Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Mar 12;2015(3):CD008226.
doi: 10.1002/14651858.CD008226.pub3.

Lipid-lowering efficacy of atorvastatin

Stephen P Adams  1 , Michael Tsang, James M Wright
Affiliations
Meta-Analysis

Lipid-lowering efficacy of atorvastatin

Stephen P Adams et al. Cochrane Database Syst Rev. .

Abstract

Background: This represents the first update of this review, which was published in 2012. Atorvastatin is one of the most widely prescribed drugs and the most widely prescribed statin in the world. It is therefore important to know the dose-related magnitude of effect of atorvastatin on blood lipids.

Objectives: Primary objective To quantify the effects of various doses of atorvastatin on serum total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol and triglycerides in individuals with and without evidence of cardiovascular disease. The primary focus of this review was determination of the mean per cent change from baseline of LDL-cholesterol. Secondary objectives • To quantify the variability of effects of various doses of atorvastatin.• To quantify withdrawals due to adverse effects (WDAEs) in placebo-controlled randomised controlled trials (RCTs).

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 11, 2013), MEDLINE (1966 to December Week 2 2013), EMBASE (1980 to December Week 2 2013), Web of Science (1899 to December Week 2 2013) and BIOSIS Previews (1969 to December Week 2 2013). We applied no language restrictions.

Selection criteria: Randomised controlled and uncontrolled before-and-after trials evaluating the dose response of different fixed doses of atorvastatin on blood lipids over a duration of three to 12 weeks.

Data collection and analysis: Two review authors independently assessed eligibility criteria for studies to be included and extracted data. We collected information on withdrawals due to adverse effects from placebo-controlled trials.

Main results: In this update, we found an additional 42 trials and added them to the original 254 studies. The update consists of 296 trials that evaluated dose-related efficacy of atorvastatin in 38,817 participants. Included are 242 before-and-after trials and 54 placebo-controlled RCTs. Log dose-response data from both trial designs revealed linear dose-related effects on blood total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides. The Summary of findings table 1 documents the effect of atorvastatin on LDL-cholesterol over the dose range of 10 to 80 mg/d, which is the range for which this systematic review acquired the greatest quantity of data. Over this range, blood LDL-cholesterol is decreased by 37.1% to 51.7% (Summary of findings table 1). The slope of dose-related effects on cholesterol and LDL-cholesterol was similar for atorvastatin and rosuvastatin, but rosuvastatin is about three-fold more potent. Subgroup analyses suggested that the atorvastatin effect was greater in females than in males and was greater in non-familial than in familial hypercholesterolaemia. Risk of bias for the outcome of withdrawals due to adverse effects (WDAEs) was high, but the mostly unclear risk of bias was judged unlikely to affect lipid measurements. Withdrawals due to adverse effects were not statistically significantly different between atorvastatin and placebo groups in these short-term trials (risk ratio 0.98, 95% confidence interval 0.68 to 1.40).

Authors' conclusions: This update resulted in no change to the main conclusions of the review but significantly increases the strength of the evidence. Studies show that atorvastatin decreases blood total cholesterol and LDL-cholesterol in a linear dose-related manner over the commonly prescribed dose range. New findings include that atorvastatin is more than three-fold less potent than rosuvastatin, and that the cholesterol-lowering effects of atorvastatin are greater in females than in males and greater in non-familial than in familial hypercholesterolaemia. This review update does not provide a good estimate of the incidence of harms associated with atorvastatin because included trials were of short duration and adverse effects were not reported in 37% of placebo-controlled trials.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

1
1
2
2
3
3
Values represent the results of each trial for each dose comparison. The standard error bars cannot be seen because they all lie within the points.
4
4
Values represent the results of each trial for each dose comparison. The standard error bars cannot be seen because they all lie within the points.
5
5
Values represent the results of each trial for each dose comparison. The standard error bars cannot be seen because they all lie within the points.
6
6
Values represent the results of each trial for each dose comparison. The standard error bars cannot be seen because they all lie within the points.
7
7
Risk of bias graph: authors' judgements about each risk of bias item presented as percentages across all included studies.
8
8
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Atorvastatin 5.0 mg vs control, Outcome 1 Total cholesterol.
1.2
1.2. Analysis
Comparison 1 Atorvastatin 5.0 mg vs control, Outcome 2 LDL‐cholesterol.
1.3
1.3. Analysis
Comparison 1 Atorvastatin 5.0 mg vs control, Outcome 3 HDL‐cholesterol.
1.4
1.4. Analysis
Comparison 1 Atorvastatin 5.0 mg vs control, Outcome 4 Triglycerides.
2.1
2.1. Analysis
Comparison 2 Atorvastatin 10 mg vs control, Outcome 1 Total cholesterol.
2.2
2.2. Analysis
Comparison 2 Atorvastatin 10 mg vs control, Outcome 2 Total cholesterol.
2.3
2.3. Analysis
Comparison 2 Atorvastatin 10 mg vs control, Outcome 3 LDL‐cholesterol.
2.4
2.4. Analysis
Comparison 2 Atorvastatin 10 mg vs control, Outcome 4 LDL‐cholesterol.
2.5
2.5. Analysis
Comparison 2 Atorvastatin 10 mg vs control, Outcome 5 HDL‐cholesterol.
2.6
2.6. Analysis
Comparison 2 Atorvastatin 10 mg vs control, Outcome 6 HDL‐cholesterol.
2.7
2.7. Analysis
Comparison 2 Atorvastatin 10 mg vs control, Outcome 7 Triglycerides.
2.8
2.8. Analysis
Comparison 2 Atorvastatin 10 mg vs control, Outcome 8 Triglycerides.
3.1
3.1. Analysis
Comparison 3 Atorvastatin 20 mg vs control, Outcome 1 Total cholesterol.
3.2
3.2. Analysis
Comparison 3 Atorvastatin 20 mg vs control, Outcome 2 Total cholesterol.
3.3
3.3. Analysis
Comparison 3 Atorvastatin 20 mg vs control, Outcome 3 LDL‐cholesterol.
3.4
3.4. Analysis
Comparison 3 Atorvastatin 20 mg vs control, Outcome 4 LDL‐cholesterol.
3.5
3.5. Analysis
Comparison 3 Atorvastatin 20 mg vs control, Outcome 5 HDL‐cholesterol.
3.6
3.6. Analysis
Comparison 3 Atorvastatin 20 mg vs control, Outcome 6 HDL‐cholesterol.
3.7
3.7. Analysis
Comparison 3 Atorvastatin 20 mg vs control, Outcome 7 Triglycerides.
3.8
3.8. Analysis
Comparison 3 Atorvastatin 20 mg vs control, Outcome 8 Triglycerides.
4.1
4.1. Analysis
Comparison 4 Atorvastatin 40 mg vs control, Outcome 1 Total cholesterol.
4.2
4.2. Analysis
Comparison 4 Atorvastatin 40 mg vs control, Outcome 2 Total cholesterol.
4.3
4.3. Analysis
Comparison 4 Atorvastatin 40 mg vs control, Outcome 3 LDL‐cholesterol.
4.4
4.4. Analysis
Comparison 4 Atorvastatin 40 mg vs control, Outcome 4 LDL‐cholesterol.
4.5
4.5. Analysis
Comparison 4 Atorvastatin 40 mg vs control, Outcome 5 HDL‐cholesterol.
4.6
4.6. Analysis
Comparison 4 Atorvastatin 40 mg vs control, Outcome 6 HDL‐cholesterol.
4.7
4.7. Analysis
Comparison 4 Atorvastatin 40 mg vs control, Outcome 7 Triglycerides.
4.8
4.8. Analysis
Comparison 4 Atorvastatin 40 mg vs control, Outcome 8 Triglycerides.
5.1
5.1. Analysis
Comparison 5 Atorvastatin 80 mg vs control, Outcome 1 Total cholesterol.
5.2
5.2. Analysis
Comparison 5 Atorvastatin 80 mg vs control, Outcome 2 Total cholesterol.
5.3
5.3. Analysis
Comparison 5 Atorvastatin 80 mg vs control, Outcome 3 LDL‐cholesterol.
5.4
5.4. Analysis
Comparison 5 Atorvastatin 80 mg vs control, Outcome 4 LDL‐cholesterol.
5.5
5.5. Analysis
Comparison 5 Atorvastatin 80 mg vs control, Outcome 5 HDL‐cholesterol.
5.6
5.6. Analysis
Comparison 5 Atorvastatin 80 mg vs control, Outcome 6 HDL‐cholesterol.
5.7
5.7. Analysis
Comparison 5 Atorvastatin 80 mg vs control, Outcome 7 Triglycerides.
5.8
5.8. Analysis
Comparison 5 Atorvastatin 80 mg vs control, Outcome 8 Triglycerides.
6.1
6.1. Analysis
Comparison 6 All doses vs control, Outcome 1 WDAEs.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

3T study 2003 {published data only}
    1. Miettinen TA, Gylling H, Lindbohm N, Miettinen TE, Rajaratnam RA, Relas H, Finnish Treat‐to‐Target Study Investigators. Serum non‐cholesterol sterols during inhibition of cholesterol synthesis by statins. Journal of Laboratory & Clinical Medicine 2003;141(2):131‐7. [MEDLINE: ] - PubMed
    1. Olsson AG, Eriksson M, Johnson O, Kjellstrom T, Lanke J, Larsen ML, et al. A 52‐week, multicenter, randomized, parallel‐group, double‐blind, double‐dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low‐density lipoprotein cholesterol and triglyceride targets: The Treat‐to‐Target (3T) study. Clinical Therapeutics 2003;25(1):119‐38. [MEDLINE: ] - PubMed
    1. Olsson AG, Eriksson M, Johnson O, Kjellstrom T, Lanke J, Lytken M, et al. Effect of atorvastatin and simvastatin in obtaining targets for lipids in secondary prevention. The treat‐to‐target study (3T). Atherosclerosis 2000;151(1):46. [CENTRAL: CN‐00447036]
    1. Seljeflot I, Tonstad S, Hjermann I, Arnesen H. Improved fibrinolysis after 1‐year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thrombosis Research 2002;105(4):285‐90. [MEDLINE: ] - PubMed
    1. Seljeflot I, Tonstad S, Hjermann I, Arnesen H. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis 2002;162(1):179‐85. [MEDLINE: ] - PubMed
ACCESS 2001 {published data only}
    1. Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C. Correlation of non‐high‐density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non‐high‐density lipoprotein cholesterol levels. American Journal of Cardiology 2001;88(3):265‐9. [MEDLINE: ] - PubMed
    1. Campese VM, Kostis JB, Shear CL. Comparing the efficacy of statins in various patient subgroups in the atorvastatin comparative cholesterol efficacy and safety study (ACCESS). Atherosclerosis 2000;151(1):315. [CENTRAL: CN‐00444655]
    1. Center for Drug Evaluation and Research. ACCESS clinical trial. Drugs @ FDA 2001;Application Number: 20‐702/S025:1‐23.
    1. Edmundowicz D, Andrews TC, Shear CL. Comparing treatment success with statins: results from the atorvastatin comparative cholesterol efficacy and safety study (ACCESS). Atherosclerosis 2000;151(1):277. [CENTRAL: CN‐00445197]
    1. Smith DG, McBurney CR. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS). Pharmacoeconomics 2003;21 Suppl 1:13‐23. [MEDLINE: ] - PubMed
ADVOCATE 2003 {published data only}
    1. Bays H. Combination niacin and statin therapy compared with monotherapy. Cardiology Review 2003;20(11):34‐7. [EMBASE: 2003430296]
    1. Bays HE, Dujovne CA, MCGovern ME, White TE, Kashyap ML, Hutcheson AG, et al. Comparison of once‐daily, niacin extended‐release/lovastatin with standard doses of atorvastatin and simvastatin (The Advicor versus Other Cholesterol‐Modulating Agents Trial Evaluation [ADVOCATE]). American Journal of Cardiology 2003;91(6):667‐72. [MEDLINE: ] - PubMed
    1. Bays HE, McGovern ME. Once‐daily niacin extended release/lovastatin combination tablet has more favourable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Preventive Cardiology 2003;6(4):179‐88. [MEDLINE: ] - PubMed
Alaupovic 1997 {published data only}
    1. Alaupovic P, Heinonen T, Shurzinske L, Black DM. Effect of a new HMG‐CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels. Atherosclerosis 1997;133(1):123‐33. [MEDLINE: ] - PubMed
Almroth 2009 {published data only}
    1. Almroth H, Hoglund N, Boman K, Englund A, Jensen S, Kjellman B, et al. Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo‐controlled multicentre study. European Heart Journal 2009;30(7):827‐33. [MEDLINE: ] - PubMed
ALPIN 2004 {unpublished data only}
    1. Pfizer Inc. Impact of Atorvastatin on the Distribution, Composition and Metabolism of LDL (Low Density Lipoprotein) and HDL (High Density Lipoprotein) Subfractions: a Double‐Blind Placebo‐Controlled Phase IV Study With Patients Suffering From Combined Hyperlipidemia and Diabetes ‐ Atorvastatin and LDL Profile In NIDDM (ALPIN Study). Protocol No. A2581040 2004. [NCT00640549]
    1. Wunderlich T, Hoffmann M, Friedrich I, Wieland H, Hanefeld M, Marz W, et al. Atorvastatin and LDL profile in NIDDM (Alpin study). Atherosclerosis Supplements 2006;7(3):581. [IDS Number: 064MN]
Amudha 2008 {published data only}
    1. Amudha K, Choy AM, Mustafa MR, Lang CC. Short‐term effect of atorvastatin on endothelial function in healthy offspring of parents with type 2 diabetes mellitus. Cardiovascular Therapeutics 2008;26(4):253‐61. [MEDLINE: ] - PubMed
Anagnostis 2011 {published data only}
    1. Anagnostis P, Selalmatzidou D, Polyzos SA, Panagiotou A, Slavakis A, Panagiotidou A, et al. Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non‐diabetic patients with dyslipidaemia: a prospective randomised open‐label study. International Journal of Clinical Practice 2011;65(6):679‐83. [MEDLINE: ] - PubMed
ANDROMEDA 2007 {published data only}
    1. Betteridge DJ, Gibson JM. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabetic Medicine 2007;24(5):541‐9. [MEDLINE: ] - PubMed
    1. Betteridge DJ, Gibson JM, ANDROMEDA Study Investigators. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabetic Medicine 2007;24(5):541‐9. [EMBASE: 2007212120] - PubMed
    1. Betteridge DJ, Gibson JM, Sager PT. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C‐reactive protein (< 2 mg/L) and low‐density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). American Journal of Cardiology 2007;100(8):1245‐8. [MEDLINE: ] - PubMed
Ansquer 2009 {published data only}
    1. Ansquer JC, Corda C, Malicot K, Jessent V. Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low‐density lipoprotein profile in dyslipidemic patients: a 12‐week, multicenter, randomized, open‐label, parallel‐group study. Current Therapeutic Research Clinical and Experimental 2009;70(2):71‐93. [EMBASE: 2009218875] - PMC - PubMed
Arazi 2008 {published data only}
    1. Arazi SS, Genvigir FD, Willrich MA, Hirata MH, Dorea EL, Bernik M, et al. Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering‐lipids response. Clinica Chimica Acta 2008;393(2):119‐24. [MEDLINE: ] - PubMed
Arca 2007a {published data only}
    1. Arca M, Cambuli VM, Montali A, Sentinelli F, Filippi E, Campagna F, et al. Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid‐lowering treatment. Nutrition, Metabolism, and Cardiovascular Diseases 2009; Vol. 19, issue 9:660‐6. [EMBASE: 19632099] - PubMed
    1. Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, et al. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia. Metabolism: Clinical & Experimental 2007;56(11):1534‐41. [MEDLINE: ] - PubMed
Arca 2007b {published data only}
    1. Arca M, Natoli S, Micheletta F, Riggi S, Angelantonio E, Montali A, et al. Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy. Free Radical Biology & Medicine 2007;42(5):698‐705. [MEDLINE: ] - PubMed
ARIES 2006 {published data only}
    1. AstraZeneca. A 6‐week, randomized, open‐label, comparative study to evaluate the efficacy and safety of rosuvastatin and atorvastatin in the treatment of hypercholesterolemia in African‐American subjects. Protocol No. D3560L00022/4522US0002 2003.
    1. Ferdinand KC, Clark LT, Watson KE, Neal RC, Brown CD, Kong BW, et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African‐American patients in a six‐week trial. American Journal of Cardiology 2006;97(2):229‐35. [MEDLINE: ] - PubMed
ASSET 2001 {published data only}
    1. Insull W, Kafonek S, Goldner D, Zieve F. Comparison of efficacy and safety of atorvastatin (10 mg) with simvastatin (10 mg) at six weeks. American Journal of Cardiology 2001;87(5):554‐9. [MEDLINE: ] - PubMed
    1. Insull W, Kafonek S, Goldner DB, Zieve F. Efficacy and safety of atorvastatin versus simvastatin in mixed dyslipidemic patients with and without type 2 diabetes during 54 weeks. Atherosclerosis Supplement 2001;2(2):87. [CENTRAL: CN‐00445855]
AstraZeneca 2010 {unpublished data only}
    1. AstraZeneca. A randomised, double‐blind trial to compare the efficacy of rosuvastatin 5 and 10 mg to atorvastatin 10 mg in the treatment of high risk patients with hypercholesterolemia followed by an open label treatment period with rosuvastatin up‐titrated to the maximum dose of 20 mg for those patients who do not achieve goal. NCT00683618 D356FC00007 2010.
ASTRO‐2 2009 {published data only}
    1. Yamazaki T, Kurabayashi M, ASTRO‐2 Study Group. A randomized controlled study to compare the effect of rosuvastatin 5mg with atorvastatin 10mg on plasma lipids in Japanese patients with hypercholesterolemia (ASTRO‐2). Annals of Vascular Diseases 2009;2(3):159‐73. [PUBMED: 23555376] - PMC - PubMed
Atalar 2002 {published data only}
    1. Atalar E, Ozmen F, Haznedaroglu I, Acil T, Ozer N, Ovunc K, et al. Effects of short‐term atorvastatin treatment on global fibrinolytic capacity, and sL‐selectin and sFas levels in hyperlipidemic patients with coronary artery disease. International Journal of Cardiology 2002;84(2‐3):227‐31. [MEDLINE: ] - PubMed
ATLANTIKA 2008 {published data only}
    1. Mareev VI. Atorvastatin in the treatment of high risk patients with ischemic heart disease and dyslipidemia. Safety assessment in the Russian Multicenter Study ATLANTIKA [in Russian]. Kardiologiia 2010; Vol. 50, issue 9:4‐14. [EMBASE: 21118160] - PubMed
    1. Mareev VI, Belenkov IN, Oganov RG, Barbik‐Zhagar B, Mareev VI, Belenkov IN, et al. Atorvastatin in treatment of patients with coronary heart disease and dyslipidemia and high general risk: efficiency and safety estimation. Design and main results of ATLANTIKA [in Russian]. Kardiologiia 2008;48(11):4‐13. [MEDLINE: ] - PubMed
ATOROS 2006 {published data only}
    1. Milionis HJ, Rizos E, Kostapanos M, Filippatos TD, Gazi IF, Ganotakis ES, et al. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Current Medical Research & Opinion 2006;22(6):1123‐31. [MEDLINE: ] - PubMed
AVALON 2006 {published data only}
    1. Cohn JN, Wilson DJ, Neutel J, Houston M, Weinberger MH, Grimm R Jr, et al. Co‐administered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. American Journal of Hypertension 2009; Vol. 22, issue 2:137‐44. [MEDLINE: ] - PubMed
    1. Messerli FH, Bakris GL, Ferrera D, Houston MC, Petrella RJ, Flack JM, et al. Efficacy and safety of co‐administered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. Journal of Clinical Hypertension 2006;8(8):571‐81. [MEDLINE: ] - PMC - PubMed
    1. Pfizer inc. A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled and Open‐Label Evaluation of the Safety and Efficacy of Dual Therapy With Atorvastatin Plus Amlodipine When Compared to Either Therapy Alone in the Treatment of Patients With Simultaneous Hyperlipidemia and Hypertension (The Avalon Study). Protocol No. A3841001 2003.
Bach‐Ngohou 2005 {published data only}
    1. Bach‐Ngohou K, Ouguerram K, Frenais R, Maugere P, Ripolles‐Piquer B, Zair Y, et al. Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes. Journal of Pharmacology & Experimental Therapeutics 2005;315(1):363‐9. [MEDLINE: ] - PubMed
Bahadir 2009 {published data only}
    1. Bahadir MA, Oguz A, Uzunlulu M, Bahadir O, Bahadir MA, Oguz A, et al. Effects of different statin treatments on small dense low‐density lipoprotein in patients with metabolic syndrome. Journal of Atherosclerosis & Thrombosis 2009;16(5):684‐90. [MEDLINE: ] - PubMed
Bakker‐Arkema 1996 {published data only}
    1. Bakker‐Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, et al. Efficacy and safety of a new HMG‐CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996;275(2):128‐33. [MEDLINE: ] - PubMed
    1. Bakker‐Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, et al. Efficacy and safety of a new HMG‐CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. Perfusion 1996;9(5):163‐8. [IDS Number: UP394] - PubMed
    1. Le NA, Innis‐Whitehouse W, Li X, Bakker‐Arkema R, Black D, Brown WV. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism 2000;49(2):167‐77. [MEDLINE: ] - PubMed
Balakhonova 2002 {published data only}
    1. Balakhonova TV, Pogorelova OA, Susekov AV, Kobylianskii AG, Kuznetsova TV, Tvorogova MG, et al. Effect of atorvastatin on endothelial function in patients with familial hypercholesterolemia [in Russian]. Kardiologiia 2002;42(1):15‐21. [MEDLINE: ] - PubMed
Ballantyne 2004 {published data only}
    1. Ballantyne C, Blazing M, King T, Brady W, Palmisano J. Efficacy of co‐administered ezetimibe plus simvastatin versus atorvastatin alone in adults with hypercholesterolemia. Atherosclerosis Supplements 2004;5(1):105. [IDS Number: 823UO]
    1. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co‐administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. American Journal of Cardiology 2004;93(12):1487‐94. [MEDLINE: ] - PubMed
    1. Merck, Co Inc. A Multicenter, Double‐Blind, Randomized, Parallel Group, 28‐Week Study to Evaluate the Efficacy and Safety of Ezetimibe and Simvastatin Co‐Administration Versus Atorvastatin in Patients With Hypercholesteremia. Merck Protocol Number: 025‐0 2003.
Barter 2000 {published data only}
    1. Barter PJ, O'Brien RC. Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice. Atherosclerosis 2000;149(1):199‐205. [MEDLINE: ] - PubMed
Bays 2011 {published data only}
    1. Bays HE, Schwartz S, Littlejohn T III, Kerzner B, Krauss RM, Karpf DB, et al. MBX‐8025, a novel peroxisome proliferator receptor‐agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. Journal of Clinical Endocrinology and Metabolism 2011;96(9):2889‐97. [EMBASE: 2011500391] - PubMed
Berthold 2004 {published data only}
    1. Berthold HK, Unverdorben S, Zittermann A, Degenhardt R, Baumeister B, Unverdorben M, et al. Age‐dependent effects of atorvastatin on biochemical bone turnover markers: a randomized controlled trial in postmenopausal women. Osteoporosis International 2004;15(6):459‐67. [MEDLINE: ] - PubMed
Bertolami 2002 {published data only}
    1. Bertolami MC, Ramires JAF, Nicolau JC, Novazzi JP, Bodanese LC, Giannini SD. Open, randomized, comparative study of atorvastatin and simvastatin, after 12 weeks treatment, in patients with hypercholesterolemia alone or with combined hypertriglyceridemia [Comparacao da seguranca e eficacia da atorvastatina com a sinvastatina apos doze semanas, em portadores de hipercolesterolemia pura ou associada a hipertrigliceridemia]. Revista Brasileira de Medicina 2002;59(8):577‐84. [EMBASE: 2002368925]
Best 1996 {published data only}
    1. Best JD, Micholson GC, O'Neal DN, Kotowicz MA, Tebbutt NC, Chan K‐W, et al. Atorvastatin and simvastatin reduce elevated cholesterol in non‐insulin dependent diabetes. Diabetes, Nutrition and Metabolism 1996;9(2):74‐80. [EMBASE: 1996183161]
Bevilacqua 2004 {published data only}
    1. Bevilacqua M, Guazzini B, Righini V, Barrella M, Toscano R, Chebat E. Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high‐density lipoprotein cholesterol levels: a 4‐month, prospective, open‐label, randomized, blinded ‐ end point (probe) trial. Current Therapeutic Research Clinical and Experimental 2004;65(4):330‐44. [EMBASE: 2004439205] - PMC - PubMed
Blagden 2007 {published data only}
    1. Blagden MD, Chipperfield R, Blagden MD, Chipperfield R. Efficacy and safety of ezetimibe co‐administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Current Medical Research & Opinion 2007;23(4):767‐75. [MEDLINE: ] - PubMed
Bloomfield 2009 {published data only}
    1. Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW III, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. American Heart Journal 2009;157(2):352‐60. [MEDLINE: ] - PubMed
Bo 2001 {published data only}
    1. Bo M, Nicolello MT, Fiandra U, Mercadante G, Piliego T, Fabris F. Treatment of heterozygous familial hypercholesterolemia: atorvastatin versus simvastatin. Atherosclerosis Supplement 2001;2(2):97‐8. [CENTRAL: CN‐00444460] - PubMed
    1. Bo M, Nicolello MT, Fiandra U, Mercadante G, Piliego T, Fabris F. Treatment of heterozygous familial hypercholesterolemia: atorvastatin vs simvastatin. Nutrition Metabolism and Cardiovascular Disease 2001;11(1):17‐24. [MEDLINE: ] - PubMed
Bogsrud 2013 {published data only}
    1. Bogsrud MP, Langslet G, Ose L, Arnesen KE, Stuen MC, Malt UF, et al. No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin‐induced myopathy. Scandinavian Cardiovascular Journal 2013;47(2):80‐7. [MEDLINE: ] - PubMed
Branchi 1999 {published data only}
    1. Branchi A, Fiorenza AM, Rovelli A, Torri A, Muzio F, Macor S, et al. Lowering effects of four different statins on serum triglyceride level. European Journal of Clinical Pharmacology 1999;55(7):499‐502. [MEDLINE: ] - PubMed
Branchi 2001 {published data only}
    1. Branchi A, Fiorenza AM, Torri A, Muzio F, Berra C, Colombo E, et al. Effects of low doses of simvastatin and atorvastatin on high‐density lipoprotein cholesterol levels in patients with hypercholesterolemia. Clinical Therapeutics 2001;23(6):851‐7. [MEDLINE: ] - PubMed
    1. Branchi A, Fiorenza AM, Torri A, Muzio F, Rovellini A, Berra C, et al. Effect of atorvastatin 10 mg and of simvastatin 20 mg on serum triglyceride level. Atherosclerosis 2000;151(1):47. [CENTRAL: CN‐00444522]
    1. Branchi A, Fiorenza AM, Torri A, Muzio F, Rovellini A, Berra C, et al. Effects of atorvastatin 10 mg and simvastatin 20 mg on serum triglyceride levels in patients with hypercholesterolemia. Current Therapeutic Research 2001;62(5):408‐15. [EMBASE: 2001204501]
Branchi 2002 {published data only}
    1. Branchi A, Fiorenza AM, Torri A, Muzio F, Colombo E, Valle ED, et al. Atorvastatin increases HDL cholesterol in hypercholesterolemic patients. Evidence of a relationship with baseline HDL cholesterol. Nutrition Metabolism & Cardiovascular Disease 2002;12(1):24‐8. [MEDLINE: ] - PubMed
Broncel 2005 {published data only}
    1. Broncel M, Marczyk I, Chojnowska‐Jezierska J, Michalska M, Sikora J, Kostka B. The comparison of simvastatin and atorvastatin effects on hemostatic parameters in patients with hyperlipidemia type II [Porownanie wplywu simwastatyny i atorwastatyny na wybrane parametry ukladu krzepniecia u chorych z hiperlipidemia typu II]. Polski Merkuriusz Lekarski 2005;18(106):380‐4. [MEDLINE: ] - PubMed
Brown 1998 {published data only}
    1. Brown AS, Bakker‐Arkema RG, Yellen L, Henley RW Jr, Guthrie R, Campbell CF, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program‐recommended low‐density‐lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. Journal of the American College of Cardiology 1998;32(3):665‐72. [MEDLINE: ] - PubMed
Bruni 2003 {published data only}
    1. Bruni F, Puccetti L, Pasqui AL, Pastorelli M, Bova G, Cercignani M, et al. Different effect induced by treatment with several statins on monocyte tissue factor expression in hypercholesterolemic subjects. Clinical & Experimental Medicine 2003;3(1):45‐53. [MEDLINE: ] - PubMed
Bruni 2004 {published data only}
    1. Bruni F, Pasqui AL, Pastorelli M, Bova G, Renzo M, Cercignani M, et al. Effect of atorvastatin on different fibrinolysis mechanisms in hypercholesterolemic subjects. International Journal of Cardiology 2004;95(2‐3):269‐74. [MEDLINE: ] - PubMed
Bruni 2005 {published data only}
    1. Bruni F, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, et al. Different effect of statins on platelet oxidized‐LDL receptor (CD36 and LOX‐1) expression in hypercholesterolemic subjects. Clinical & Applied Thrombosis/Hemostasis 2005;11(4):417‐28. [MEDLINE: ] - PubMed
Budinski 2009 {published data only}
    1. Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clinical Lipidology 2009;4(3):291‐302. [IDS Number: 455FM]
Buldak 2012 {published data only}
    1. Buldak L, DulawaBuldak A, Labuzek K, Okopien B. Effects of 90‐day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose. International Journal of Clinical Pharmacology & Therapeutics 2012;50(11):805‐13. [MEDLINE: ] - PubMed
CAP 2008 {published data only}
    1. Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, et al. Comparative effects of 10‐mg versus 80‐mg atorvastatin on high‐sensitivity C‐reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clinical Therapeutics 2008;30(12):2298‐313. [EMBASE: 2009030462] - PubMed
    1. McPherson R, Bonnet J, Tedgui A, Martineau P, Simoneau D, Nozza A, et al. Atorvastatin's effect on inflammatory markers (hsCRP, IL‐6 and IL‐18) in the comparative atorvastatin pleiotropic effects (CAP) study. Canadian Journal of Cardiology 2007;23 Suppl C:222C‐3C. [PREV200800219825]
    1. Pfizer Inc. A Multicenter, Randomized Double‐Blind Study Comparing the Pleiotropic Effects of Atorvastatin 10 mg and 80 mg Over a 26‐Week Period in Subjects With Coronary Atherosclerosis (CAP: Comparative Atorvastatin Pleiotropic Effects). NCT00163202 Protocol No. A2581065 2005.
Castano 2003a {published data only}
    1. Castano G, Mas R, Fernandez L, Illnait J, Mesa M, Alvarez E, et al. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. Drugs & Aging 2003;20(2):153‐63. [MEDLINE: ] - PubMed
Castano 2003b {published data only}
    1. Castano G, Fernandez L, Mas R, Illnait J, Mesa M, Fernandez JC. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus. Clinical Drug Investigation 2003;23(10):639‐50. [EMBASE: 2003424476] - PubMed
Castro 2008 {published data only}
    1. Castro PF, Miranda R, Verdejo HE, Greig D, Gabrielli LA, Alcaino H, et al. Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity. Journal of Heart & Lung Transplantation 2008;27(4):435‐41. [MEDLINE: ] - PubMed
Catalano 2009 {published data only}
    1. Catalano G, Julia Z, Frisdal E, Vedie B, Fournier N, Goff W, et al. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Arteriosclerosis, Thrombosis & Vascular Biology 2009;29(2):268‐75. [MEDLINE: ] - PubMed
Cerda 2010 {published data only}
    1. Cerda A, Genvigir FDV, Arazi SS, Hirata MH, Dorea EL, Bernik MMS, et al. Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin. Clinica Chimica Acta; International Journal of Clinical Chemistry 2010;411(9‐10):631‐7. [MEDLINE: ] - PubMed
    1. Cerda A, Genvigir FDV, Rodrigues AC, Willrich MAV, Dorea EL, Bernik MMS, et al. Influence of polymorphisms and cholesterol‐lowering treatment on SCARB1 mRNA expression. Journal of Atherosclerosis and Thrombosis 2011;18(8):640‐51. [EMBASE: 2011474438] - PubMed
CEZAR 2009 {published data only}
    1. Ostad Mir A, Eggeling S, Tschentscher P, Schwedhelm E, Boger R, Wenzel P, et al. Flow‐mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study. Atherosclerosis 2009;205(1):227‐32. [MEDLINE: ] - PubMed
CHALLENGE 2002 {published data only}
    1. Karalis DG, Ross AM, Vacari RM, Zarren H, Kafonek S, Tambone L. Comparing the efficacy of atorvastatin vs simvastatin in hypercholesterolemic patients with and without CHD. Atherosclerosis Supplement 2001;2(2):95. [CENTRAL: CN‐00446012]
    1. Karalis DG, Ross AM, Vacari RM, Zarren H, Scott R. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. American Journal of Cardiology 2002;89(6):667‐71. [MEDLINE: ] - PubMed
    1. Karalis DG, Ross AM, Vacari RM, Zarren H, Scott R. Efficacy and safety of atorvastatin and simvastatin. Cardiology Review 2003;20(2):30‐3. [EMBASE: 2003099804] - PubMed
Chan 2002 {published data only}
    1. Chan DC, Nguyen MN, Watts GF, Ooi EM, Barrett PHR. Effects of atorvastatin and n‐3 fatty acid supplementation on VLDL apolipoprotein C‐III kinetics in men with abdominal obesity. The American Journal of Clinical Nutrition. United States: Metabolic Research Centre School of MedicinePharmacology Royal Perth Hospital University of Western Australia Perth Western Australia., 2010; Vol. 91, issue 4:900‐6. [MEDLINE: ] - PubMed
    1. Chan DC, Watts GF, Barrett PH, Beilin LJ, Mori TA. Effect of atorvastatin and fish oil on plasma high‐sensitivity C‐reactive protein concentrations in individuals with visceral obesity. Clinical Chemistry 2002;48(6):877‐83. [MEDLINE: ] - PubMed
    1. Chan DC, Watts GF, Barrett PH, Beilin LJ, Redgrave TG, Mori TA. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B‐100 kinetics in insulin‐resistant obese male subjects with dyslipidemia. Diabetes 2002;51(8):2377‐86. [MEDLINE: ] - PubMed
    1. Chan DC, Watts GF, Barrett PH, Mori TA, Beilin LJ, Redgrave TG. Mechanism of action of a 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B‐100 kinetics in visceral obesity. Journal of Clinical Endocrinology & Metabolism 2002;87(5):2283‐9. [MEDLINE: ] - PubMed
    1. Chan DC, Watts GF, Barrett PHR, Martins IJ, James AP, Mamo JCL, et al. Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test. Journal of Lipid Research 2002;43(5):706‐12. [MEDLINE: ] - PubMed
Chan 2008 {published data only}
    1. Chan KC, Chou HH, Huang CN, Chou MC. Atorvastatin administration after percutaneous coronary intervention in patients with coronary artery disease and normal lipid profiles: impact on plasma adiponectin level. Clinical Cardiology 2008;31(6):253‐8. [MEDLINE: ] - PMC - PubMed
Chen 2013 {published data only}
    1. Chen F, Maccubbin D, Yan L, Sirah W, Chen E, Sisk CM, et al. Lipid‐altering efficacy and safety profile of co‐administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. International Journal of Cardiology 2013;167(1):225‐31. [EMBASE: 2013353165] - PubMed
CHESS 2003 {published data only}
    1. Ballantyne CM, Blazing MA, Hunninghake DB, Davidson MH, Yuan Z, DeLucca P, et al. Effect on high‐density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). American Heart Journal 2003;146(5):862‐9. [MEDLINE: ] - PubMed
    1. Ballantyne CM, Hustad CM, Yuan Z, DeLucca P, Palmisano J. Efficacy and safety of simvastatin versus atorvastatin: results of the Comparative HDL‐C Efficacy and Safety Study (Chess). Atherosclerosis Supplement 2002;3(2):72. [CENTRAL: CN‐00444318]
CHEST 2003 {published data only}
    1. Ansell BJ, Watson KE, Weiss RE, Fonarow GC. hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C‐reactive protein and high‐density lipoprotein levels A clinical investigation. Heart Disease 2003;5(1):2‐7. [MEDLINE: ] - PubMed
CHIBA 2008 {published data only}
    1. Yokote K, Bujo H, Hanaoka H, Shinomiya M, Mikami K, Miyashita Y, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients. Collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 2008;201(2):345‐52. [EMBASE: 2008556198] - PubMed
    1. Yokote K, Bujo H, Hanaoka H, Shinomiya M, Mikami K, Shirai K, et al. A randomized, open‐label trial comparing the efficacy and safety of pitavastatin with atorvastatin in Japanese patients with hypercholesterolemia. Diabetes 2007;56 Suppl 1:A233. [PREV200700477138]
    1. Yokote K, Saito Y, CHIBA. Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Journal of Atherosclerosis and Thrombosis. Japan, 2009; Vol. 16, issue 3:297‐8. [MEDLINE: ] - PubMed
Cho 2011 {published data only}
    1. Cho YK, Hur SH, Han CD, Park HS, Yoon HJ, Kim H, et al. Comparison of ezetimibe/simvastatin 10/20 mg versus atorvastatin 20 mg in achieving a target low density lipoprotein‐cholesterol goal for patients with very high risk. Korean Circulation Journal 2011;41(3):149‐53. [MEDLINE: ] - PMC - PubMed
Chu 2006a {published data only}
    1. Chu CS, Lee KT, Lee MY, Su HM, Voon WC, Sheu SH, et al. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. American Journal of Cardiology 2006;97(5):646‐50. [MEDLINE: ] - PubMed
Chu 2006b {published data only}
    1. Chu CS, Kou HS, Lee CJ, Lee KT, Chen SH, Voon WC, et al. Effect of atorvastatin withdrawal on circulating coenzyme Q10 concentration in patients with hypercholesterolemia. Biofactors 2006;28(3‐4):177‐84. [MEDLINE: ] - PubMed
Chu 2006c {published data only}
    1. Chu CS, Lee KT, Lee MY, Su HM, Voon WC, Sheu SH, et al. Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia. Acta Cardiologica 2006;61(3):263‐9. [MEDLINE: ] - PubMed
Chu 2007 {published data only}
    1. Chu CS, Lee KT, Lee ST, Lu YH, Lin TH, Voon WC, et al. Effects of atorvastatin on ventricular late potentials and repolarization dispersion in patients with hypercholesterolemia. Kaohsiung Journal of Medical Sciences 2007;23(5):217‐24. [MEDLINE: ] - PMC - PubMed
Claeys 2004 {published data only}
    1. Claeys MJ, Cosyns B, Hoffer E, Carlier M, Missault L, Cools F, et al. Short‐term effect of atorvastatin on ischaemic threshold in hypercholesterolaemic patients with stable ischaemic heart disease. Acta Cardiologica 2004;59(3):269‐74. [MEDLINE: ] - PubMed
COMETS 2005 {published data only}
    1. Schuster H. Does rosuvastatin improve lipid levels in patients with the metabolic syndrome more effectively than atorvastatin?. Nature Clinical Practice Cardiovascular Medicine 2006;3(2):74‐5. [EMBASE: 2006071305] - PubMed
    1. Stalenhoef AF, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H, et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. European Heart Journal 2005;26(24):2664‐72. [MEDLINE: ] - PubMed
CORALL 2005 {published data only}
    1. Simsek S, Schalkwijk CG, Wolffenbuttel BH. Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes‐‐‐the CORALL study: associated included citation for the CORALL 2005 trial. Diabetic Medicine 2012;29(5):628‐31. [MEDLINE: ] - PubMed
    1. Wolffenbuttel BH, Franken AA, Vincent HH, Dutch Corall Study Group. Cholesterol‐lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes ‐ CORALL study. Journal of Internal Medicine 2005;257(6):531‐9. [MEDLINE: ] - PubMed
Crouse III 1999 {published data only}
    1. Crouse III Jr, Frohlich J, Ose L, Mercuri M, Tobert JA. Effects of high doses of simvastatin and atorvastatin on high‐density lipoprotein cholesterol and apolipoprotein A‐1. American Journal of Cardiology 1999;83(10):1476‐7. [MEDLINE: ] - PubMed
    1. Wiklund O, Mattsson‐Hulten L, Hurt‐Camejo E, Oscarsson J. Effects of simvastatin and atorvastatin on inflammation markers in plasma. Journal of Internal Medicine 2002;251(4):338‐47. [MEDLINE: ] - PubMed
Cubeddu 2006 {published data only}
    1. Cubeddu LX, Cubeddu RJ, Heimowitz T, Restrepo B, Lamas GA, Weinberg GB. Comparative lipid‐lowering effects of policosanol and atorvastatin: a randomized, parallel, double‐blind, placebo‐controlled trial. American Heart Journal 2006;152(5):982.e1‐5. [MEDLINE: ] - PubMed
CURVES 1998 {published data only}
    1. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study). American Journal of Cardiology 1998;81(5):582‐7. [MEDLINE: ] - PubMed
    1. Kafonek S, CURVES Investigators. The CURVES study: a comparison of the dose efficacy of atorvastatin with simvastatin, pravastatin, lovastatin, and fluvastatin. XIII WORLD CONGRESS OF CARDIOLOGY. 1998:1003‐7. [IDS Number: BL74L]
DALI 2001 {published data only}
    1. Diabetes Atorvastin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double‐blind, randomized, placebo‐controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001;24(8):1335‐41. [MEDLINE: ] - PubMed
Davidson 2002 {published data only}
    1. AstraZeneca. A 12 week, randomized, double‐blind, placebo‐controlled, multicenter trial to evaluate the efficacy and safety of ZD4522 5 mg and 10 mg and atorvastatin 10 mg in the treatment of subjects with hypercholesterolemia (4522IL/0024). Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Biostatistics 1999‐2000:12‐7. [NDA 21‐366]
    1. Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. American Journal of Cardiology 2003;91 Suppl 5A:3C‐10C. [MEDLINE: ] - PubMed
    1. Davidson M, Ma P, Stein E, Hutchinson HG, Caplan R, Raza A, et al. Rosuvastatin is more effective than atorvastatin at improving the lipid profiles of patients with primary hypercholesterolaemia. Atherosclerosis Supplements 2001;2(2):38‐9. [CENTRAL: CN‐00445003]
    1. Davidson M, Ma P, Stein EA, Gotto AM Jr, Raza A, Chitra R, et al. Comparison of effects on low‐density lipoprotein cholesterol and high‐density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. American Journal of Cardiology 2002;89(3):268‐75. [MEDLINE: ] - PubMed
Della‐Morte 2011 {published data only}
    1. Della‐Morte D, Moussa I, Elkind MS, Sacco RL, Rundek T. The short‐term effect of atorvastatin on carotid plaque morphology assessed by computer‐assisted gray‐scale densitometry: a pilot study. Neurological Research 2011;33(9):991‐4. [MEDLINE: ] - PMC - PubMed
    1. Ratchford EV, Gutierrez J, Lorenzo D, McClendon, Rundek T. Short‐term effect of atorvastatin on carotid artery elasticity: a pilot study. Stroke 2011;42(12):3460‐4. [MEDLINE: ] - PMC - PubMed
Demir 2001 {published data only}
    1. Demir M, Acarturk E, Sasmaz I, Cayli M, Kilinc Y. Effects of atorvastatin on lipid profile and coagulation parameters. Current Therapeutic Research Clinical and Experimental 2001;62(10):691‐8. [493FT]
Despres 2002 {published data only}
    1. Delaval D, Despres JP, Salomon H. Micronized fenofibrate compared to atorvastatin in low HDL‐cholesterol patients (<40 mg/dl). Atherosclerosis Supplements 2001;2(2):48‐9. [CENTRAL: CN‐00445059]
    1. Despres JP, Lemieux I, Salmon H, Delaval D. Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL‐cholesterol levels: a 12 week randomized trial. Journal of Internal Medicine 2002;251(6):490‐9. [MEDLINE: ] - PubMed
Diepeveen 2005 {published data only}
    1. Diepeveen SH, Verhoeven GW, Palen J, Dikkeschei LD, Tits LJ, Kolsters G, et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised‐controlled trial. Journal of Internal Medicine 2005;257(5):438‐45. [MEDLINE: ] - PubMed
DISCOVERY 2005 {unpublished data only}
    1. AstraZeneca. An open‐label, randomised, multi‐centre, phase IIIb/IV, parallel group study to compare the efficacy and safety of rosuvastatin and atorvastatin in subjects with type IIa and IIb hypercholesterolaemia (DISCOVERY). Protocol No. D3560L00009 2005.
DISCOVERY ALPHA 2006 {published data only}
    1. Binbrek AS, Elis A, Al‐Zaibag M, Eha J, Keber I, Cuevas AM, et al. Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: a randomized, open‐label, parallel‐group, multicenter study (DISCOVERY alpha study). Current Therapeutic Research Clinical and Experimental 2006;67(1):21‐43. [IDS Number: 024LM] - PMC - PubMed
Dobreanu 2007 {published data only}
    1. Dobreanu M, Dobreanu D, Fodor A, Bacarea A, Dobreanu M, Dobreanu D, et al. Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin. Romanian Journal of Internal Medicine 2007;45(2):193‐9. [MEDLINE: ] - PubMed
Dogra 2007 {published data only}
    1. Dogra G, Irish A, Chan D, Watts G, Dogra G, Irish A, et al. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. American Journal of Kidney Diseases 2007;49(6):776‐85. [MEDLINE: ] - PubMed
ECLIPSE 2008 {published data only}
    1. AstraZeneca. A 24‐Week, Randomised, Open‐Label, Parallel‐Group, Multicentre Study Which Compares the Efficacy and Safety of Rosuvastatin 10, 20 and 40 mg With Atorvastatin 10, 20, 40 and 80 mg When Force‐Titrated in the Treatment of Patients With Primary Hypercholesterolemia and Either a History of Coronary Heart Disease (CHD) or Clinical Evidence of Atherosclerosis or a CHD Risk Equivalent (10‐Year Risk Score >20%) ECLIPSE ‐ An Evaluation to Compare Lipid‐Lowering Effects of Rosuvastatin and Atorvastatin In Force‐Titrated Patients: a Prospective Study of Efficacy and Tolerability. Protocol No. D3569C00002 2005.
    1. Faergeman O, Hill L, Windler E, Wiklund O, Asmar R, Duffield E, et al. Efficacy and tolerability of rosuvastatin and atorvastatin when force‐titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology 2008;111(4):219‐28. [MEDLINE: ] - PubMed
Economides 2004 {published data only}
    1. Economides PA, Caselli A, Tiani E, Khaodhiar L, Horton ES, Veves A. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. Journal of Clinical Endocrinology & Metabolism 2004;89(2):740‐7. [MEDLINE: ] - PubMed
Farnier 2000 {published data only}
    1. Farnier M, Portal JJ, Maigret P. Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia. Journal of Cardiovascular Pharmacology and Therapeutics 2000;5(1):27‐32. [MEDLINE: ] - PubMed
Ferreira 2007 {published data only}
    1. Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI. Atorvastatin therapy improves endothelial‐dependent vasodilation in patients with systemic lupus erythematosus: an 8 week controlled trial. Rheumatology 2007;46(10):1560‐5. [MEDLINE: ] - PubMed
Franiak‐Pietryga 2009 {published data only}
    1. Franiak‐Pietryga I, Balcerak M, Sikora J, Duchnowicz P, Koter‐Michalak M, Stetkiewicz T, et al. The effect of atorvastatin on the erythrocyte plasma membrane and C‐reactive protein in menopausal women with metabolic syndrome. Przeglad Menopauzalny 2009;13(4):233‐8. [EMBASE: 2009617064]
Fu 2013 {published data only}
    1. Fu Q, Li YP, Gao Y, Yang SH, Lu PQ, Jia M, et al. Lack of association between SLCO1B1 polymorphism and the lipid‐lowering effects of atorvastatin and simvastatin in Chinese individuals. European Journal of Clinical Pharmacology 2013;69(6):1269‐74. - PubMed
    1. Li YP, Zhang LR, Jia M, Hu XJ. CYP3AP1 [superscript] star3 Allele Is Associated With Lipid‐Lowering Efficacy of Simvastatin and Atorvastatin in Chinese Women. Journal of Clinical Pharmacology 2011;51(2):181‐8. [International Pharmaceutical Abstracts Accession Number is 48‐04778] - PubMed
Geiss 2001 {published data only}
    1. Geiss HC, Otto C, Schwandte P, Parhofer KG. Effect of atorvastatin on low‐density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. Metabolism Clinical & Experimental 2001;50(8):983‐8. [MEDLINE: ] - PubMed
Gokkaya 2008 {published data only}
    1. Gokkaya SC, Ozden C, Levent OO, Hakan KH, Guzel O, Memis A, et al. Effect of correcting serum cholesterol levels on erectile function in patients with vasculogenic erectile dysfunction. Scandinavian Journal of Urology & Nephrology 2008;42(5):437‐40. [MEDLINE: ] - PubMed
Goldberg 2009 {published data only}
    1. Goldberg AC, Bays HE, Ballantyne CM, Kelly MT, Buttler SM, Setze CM, et al. Efficacy and safety of ABT‐335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. American Journal of Cardiology 2009;103(4):515‐22. [MEDLINE: ] - PubMed
    1. Mohiuddin SM, Thakker KM, Setze CM, Kelly MT. Evaluating optimal lipid levels in patients with mixed dyslipidemia following short‐ and long‐term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. Current Medical Research & Opinion 2011;27(5):1067‐78. [MEDLINE: ] - PubMed
Goudevenos 2000 {published data only}
    1. Goudevenos JA, Bairaktari ET, Chatzidimou KG, Milionis HJ, Mikhailidis DP, Elisaf MS. The effect of atorvastatin on serum lipids lipoprotein (a) and plasma fibrinogen levels in primary dyslipidaemia ‐ a pilot study involving serial sampling. Current Medical Research and Opinion 2000;16(4):269‐75. [MEDLINE: ] - PubMed
Grossman 2000 {unpublished data only}
    1. Grossman SS. The effect of atorvastatin on blood glucose levels in type 2 diabetic patients. DAI‐B 61/07 2000:p. 3531. [ProQuest document ID: 727719711]
Guerin 2000 {published data only}
    1. Guerin M, Lassel TS, Goff W, Farnier M, Chapman MJ. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arteriosclerosis, Thrombosis & Vascular Biology 2000;20(1):189‐97. [MEDLINE: ] - PubMed
Guerin 2002 {published data only}
    1. Guerin M, Egger P, Goff W, Soudant C, Dupuis R, Chapman MJ. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein‐mediated remodeling of triglyceride‐rich lipoprotein subspecies in type IIB hyperlipidemia. Journal of Clinical Endocrinology and Metabolism 2002;87(11):4991‐5000. [MEDLINE: ] - PubMed
    1. Guerin M, Egger P, Soudant C, Goff W, Tol A, Dupuis R, et al. Dose‐dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apo‐B‐containing lipoprotein subclasses (VLDL‐2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 2002;163(2):287‐96. [MEDLINE: ] - PubMed
Guerin 2008 {published data only}
    1. Guerin M, Goff W, Duchene E, Julia Z, Nguyen T, Thuren T. Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG‐rich lipoproteins in type IIB hyperlipidemia. Arteriosclerosis, Thrombosis & Vascular Biology 2008;28(1):148‐54. [MEDLINE: ] - PubMed
Gumprecht 2011 {published data only}
    1. Gumprecht J, Gosho M, Budinski D, Hounslow N. Comparative long‐term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20‐40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes, Obesity and Metabolism 2011;13(11):1047‐55. [EMBASE: 2011546830] - PubMed
Guo 2013 {published data only}
    1. Guo YL, Liu J, Xu RX, Zhu CG, Wu NQ, Jiang LX, et al. Short‐term impact of low‐dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9. Clinical Drug Investigation 2013;33(12):877‐83. [EMBASE: 2013791565] - PubMed
Han 2008 {published data only}
    1. Han H, Xue J, Zhang J‐Y, Xu F‐H, Wang Y‐H. Efficacy and safety of rosuvastatin and atorvastatin in aged patients with hypercholesterolemia. Chinese Journal of New Drugs and Clinical Remedies 2008;27(2):120‐3. [PREV200800281522]
Harangi 2009 {published data only}
    1. Harangi M, Mirdamadi HZ, Seres I, Sztanek F, Molnar M, Kassai A, et al. Atorvastatin effect on the distribution of high‐density lipoprotein subfractions and human paraoxonase activity. Translational Research: The Journal of Laboratory & Clinical Medicine 2009;153(4):190‐8. [MEDLINE: ] - PubMed
HD‐ROWS 2012 {published data only}
    1. Backes JM, Gibson CA, Ruisinger JF, Moriarty PM. The high‐dose rosuvastatin once weekly study (the HD‐ROWS). Journal of Clinical Lipidology 2012;6(4):362‐7. [EMBASE: 2012436875] - PubMed
HeFH 2003 {published data only}
    1. Stein E, Strutt KL, Miller E, Southworth H. Rosuvastatin (20, 40 and 80 mg) reduces LDL‐C, raises HDL‐C and achieves treatment goals more effectively than atorvastatin (20, 40 and 80 mg) in patients with heterozygous familial hypercholesterolaemia [abstract]. Atherosclerosis Supplements 2001;2(2):90‐1. [CENTRAL: CN‐00447845]
    1. Stein EA, Strutt K, Southworth H, Diggle PJ, Miller E, HeFH Study Group. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. American Journal of Cardiology 2003;92(11):1287‐93. [MEDLINE: ] - PubMed
Her 2010 {published data only}
    1. Her AY, Kim JY, Kang SM, Choi D, Jang Y, Chung N, et al. Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. Journal of Cardiovascular Pharmacology and Therapeutics 2010;15(2):167‐74. [MEDLINE: ] - PubMed
Hernandez 2011 {published data only}
    1. Hernandez C, Francisco G, Ciudin A, Chacon P, Montoro B, Llaverias G, et al. Effect of atorvastatin on lipoprotein (a) and interleukin‐10: a randomized placebo‐controlled trial. Diabetes & Metabolism 2011;37(2):124‐30. [MEDLINE: ] - PubMed
Herregods 2008 {published data only}
    1. AstraZeneca. An open‐label, randomised, multi‐centre, phase IIIb, parallel group study to compare the efficacy and safety of rosuvastatin and atorvastatin in subjects with type IIa and IIb hypercholesterolaemia. Protocol No. D3560L00011 2004.
    1. Herregods MC, Daubresse JC, Michel G, Lamotte M, Vissers E, Vandenhoven G. Discovery Belux: comparison of rosuvastatin with atorvastatin in hypercholesterolaemia. Acta Cardiologica 2008;63(4):493‐9. [MEDLINE: ] - PubMed
Hogue 2008a {published data only}
    1. Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagne C, et al. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B‐100 and B‐48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism Clinical & Experimental 2008;57(2):246‐54. [MEDLINE: ] - PubMed
Hogue 2008b {published data only}
    1. Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagne C, Couture P, et al. Differential effect of atorvastatin and fenofibrate on plasma oxidized low‐density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism: Clinical & Experimental 2008;57(3):380‐6. [MEDLINE: ] - PubMed
Hoogerbrugge 1998 {published data only}
    1. Hoogerbrugge N. Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia. Journal of Internal Medicine 1998;244(2):143‐7. [MEDLINE: ] - PubMed
Hoogerbrugge 1999 {published data only}
    1. Hoogerbrugge N, Jansen H. Atorvastatin increases low‐density lipoprotein size and enhances high‐density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia. Atherosclerosis 1999;146(1):167‐74. [MEDLINE: ] - PubMed
Huang 2012 {published data only}
    1. Huang ZQ, Wu YT, Wang R, Huang W, Chen L. Effects of pitavastatin and atorvastatin on blood lipids and blood glucose in elderly type 2 diabetic patients. Zhongguo Xinyao yu Linchuang Zazhi 2012;31(10):614‐7. [BIOSIS:PREV201300107728]
Hufnagel 2000 {published data only}
    1. Hufnagel G, Michel C, Vrtovsnik F, Queffeulou G, Kossari N, Mignon F. Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis. Nephrology Dialysis Transplantation 2000;15(5):684‐8. [MEDLINE: ] - PubMed
Hunninghake 1998 {published data only}
    1. Hunninghake D, Bakker‐Arkema RG, Wigand JP, Drehobl M, Schrott H, Early JL, et al. Treating to meet NCEP‐recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. Journal of Family Practice 1998;47(5):349‐56. [MEDLINE: ] - PubMed
Hunninghake 2001a {published data only}
    1. Hunninghake D, Insull W, Knopp R, Davidson M, Lohrbauer L, Jones P, et al. Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia. American Journal of Cardiology 2001;88(6):635‐9. [MEDLINE: ] - PubMed
Hunninghake 2001b {published data only}
    1. Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001;158(2):407‐16. [MEDLINE: ] - PubMed
Hunninghake 2003 {published data only}
    1. Hunninghake DB, Ballantyne CM, Maccubbin DL, Shah AK, Gumbiner B, Mitchel YB. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clinical Therapeutics 2003;25(6):1670‐86. [MEDLINE: ] - PubMed
Hwang 2004 {published data only}
    1. Hwang YS, Tsai WC, Lu YH, Lin CC, Chen YF. Effect of atorvastatin on the expression of CD40 ligand and P‐selectin on platelets in patients with hypercholesterolemia. American Journal of Cardiology 2004;94(3):364‐6. [MEDLINE: ] - PubMed
Ikewaki 2009 {published data only}
    1. Ikewaki K, Terao Y, Ozasa H, Nakada Y, Tohyama J, Inoue Y, et al. Effects of atorvastatin on nuclear magnetic resonance‐defined lipoprotein subclasses and inflammatory markers in patients with hypercholesterolemia. Journal of Atherosclerosis and Thrombosis 2009;16(1):51‐6. [MEDLINE: ] - PubMed
Illingworth 2001 {published data only}
    1. Illingworth DR, Crouse JR III, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AFH, et al. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Current Medical Research and Opinion 2001;17(1):43‐50. [MEDLINE: ] - PubMed
    1. Kastelein JJ, Isaacsohn JL, Ose L, Hunninghake DB, Frohlich J, Davidson MH, et al. Comparison of effects of simvastatin versus atorvastatin on high‐density lipoprotein cholesterol and apolipoprotein A‐I levels. American Journal of Cardiology 2000;86(2):221‐3. [MEDLINE: ] - PubMed
IRIS 2007 {published data only}
    1. AstraZeneca. A 6‐Week, Randomized, Open‐Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Hypercholesterolemia in South Asian Subjects (IRIS). Protocol No. D3560L00026/4522US0006 2005.
    1. Deedwania PC, Gupta M, Stein M, Ycas J, Gold A, IRIS Study Group. Comparison of rosuvastatin versus atorvastatin in South‐Asian patients at risk of coronary heart disease (from the IRIS Trial). American Journal of Cardiology 2007;99(11):1538‐43. [MEDLINE: ] - PubMed
Issa 2012 {published data only}
    1. Issa MH, Cerda A, Genvigir FD, Cavalli SA, Bertolami MC, Faludi AA, et al. Atorvastatin and hormone therapy effects on APOE mRNA expression in hypercholesterolemic postmenopausal women. Journal of Steroid Biochemistry & Molecular Biology 2012;128(3‐5):139‐44. [MEDLINE: ] - PubMed
J‐CLAS 1997 {published data only}
    1. Nakamura H, Ohashi Y, Maruhama Y, Ninomiya K, Toyota T, Oikawa S, et al. Efficacy of atorvastatin in primary hypercholesterolemia. American Journal of Cardiology 1997;79(9):1248‐52. [MEDLINE: ] - PubMed
Jin 2012 {published data only}
    1. Jin D, Wu Y, Zhao L, Guo J, Zhang K, Chen Z. Atorvastatin reduces serum HMGB1 levels in patients with hyperlipidemia. Experimental and Therapeutic Medicine 2012;4(6):1124‐6. [EMBASE: 2012594723] - PMC - PubMed
Joukhadar 2001 {published data only}
    1. Joukhadar C, Klein N, Prinz M, Schrolnberger C, Vukovich T, Wolzt M, et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thrombosis & Haemostasis 2001;85(1):47‐51. [MEDLINE: ] - PubMed
Kadikoylu 2003 {published data only}
    1. Kakikoylu G, Yukselen V, Yavasoglu I, Bolaman Z. Hemostatic effects of atorvastatin versus simvastatin. Annals of Pharmacotherapy 2003;37(4):478‐84. [MEDLINE: ] - PubMed
Kadoglou 2011 {published data only}
    1. Kadoglou NPE, Vrabas IS, Kapelouzou A, Lampropoulos S, Sailer N, Kostakis A, et al. Impact of atorvastatin on serum vaspin levels in hypercholesterolemic patients with moderate cardiovascular risk. Regulatory Peptides 2011;170(1‐3):57‐61. [MEDLINE: ] - PubMed
Kajinami 2003 {published data only}
    1. Kajinami K, Takekoshi N, Matsui S, Kanemitsu S, Okubo S, Kanayama S, et al. Effect of pretreatment vitamin D levels on in vivo effects of atorvastatin on bone metabolism in patients with heterozygous familial hypercholesterolemia. American Journal of Cardiology 2003;92(9):1113‐6. [MEDLINE: ] - PubMed
Kassai 2007 {published data only}
    1. Kassai A, Illyes L, Mirdamadi HZ, Seres I, Kalmar T, Audikovszky M, et al. The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clinical Biochemistry 2007;40(1‐2):1‐5. [MEDLINE: ] - PubMed
Keles 2008 {published data only}
    1. Keles T, Akar BN, Kayhan T, Canbay A, Sahin D, Durmaz T, et al. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL‐cholesterol and high sensitive C‐reactive protein levels. Anadolu Kardiyoloji Dergisi 2008;8(6):407‐12. [MEDLINE: ] - PubMed
Kim 2010 {published data only}
    1. Kim SH, Park K, Hong SJ, Cho YS, Sung JD, Moon GW, et al. Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double‐blind, double‐dummy clinical trial. Clinical Therapeutics 2010;32(11):1896‐905. [EMBASE: 2010647967] - PubMed
Kim 2013 {published data only}
    1. Kim SH, Seo MK, Yoon MH, Choi DH, Hong TJ, Kim HS. Assessment of the efficacy and tolerability of 2 formulations of atorvastatin in Korean adults with hypercholesterolemia: a multicenter, prospective, open‐label, randomized trial. Clinical Therapeutics 2013;35(1):77‐86. [EMBASE: 2013044605] - PubMed
Kocic 2002 {published data only}
    1. Kocic R, Pavlovic D, Kocic G, Lalic NM. Beneficial effect of atorvastatin therapy in diabetics. Atherosclerosis: Risk Factors, Diagnosis, and Treatment. Bologna: MEDIMOND S R L, 2002:321‐5. [IDS Number: BV31J ISBN: 88‐323‐2707‐4]
Koh 2010 {published data only}
    1. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK, et al. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. Journal of the American College of Cardiology 2010;55(12):1209‐16. [MEDLINE: ] - PMC - PubMed
Kom 2007 {published data only}
    1. Kom GD, Schwedhelm E, Maas R, Schneider L, Benndorf R, Boger RH. Impact of atorvastatin treatment on platelet‐activating factor acetylhydrolase and 15‐F(2trans)‐isoprostane in hypercholesterolaemic patients.. British Journal of Clinical Pharmacology 2007;63(6):672‐9. [MEDLINE: ] - PMC - PubMed
Kosmidou 2008 {published data only}
    1. Kosmidou MS, Hatzitolios AI, Adamidou A, Giannopoulos S, Raikos N, Parharidis G, et al. Effects of atorvastatin on red‐blood cell Na(+)/Li(+) countertransport in hyperlipidemic patients with and without hypertension. American Journal of Hypertension 2008;21(3):303‐9. [MEDLINE: ] - PubMed
Kotani 2012 {published data only}
    1. Kotani K, Yamada T, Miyamoto M, Ishibashi S, Taniguchi N, Gugliucci A. Influence of atorvastatin on serum amyloid A‐low density lipoprotein complex in hypercholesterolemic patients. Pharmacological Reports: PR 2012;64(1):212‐6. [EMBASE: 2012333843] - PubMed
Koter 2002 {published data only}
    1. Koter M, Broncel M, Chojnowska‐Jezierska J, Klikczynska K, Franiak I. The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type‐2 hypercholesterolemia. European Journal of Clinical Pharmacology 2002;58(8):501‐6. [MEDLINE: ] - PubMed
Kowalski 2006 {published data only}
    1. Kowalski J, Barylski M, Banach M, Grycewicz J, Irzmanski R, Pawlicki L. Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. Journal of Cardiovascular Pharmacology 2006;48(4):143‐7. [MEDLINE: ] - PubMed
Kukharchuk 2007 {published data only}
    1. Kukharchuk VV, Kaminni AI, Kukharchuk VV, Kaminni AI. Assessment of hypolipidemic efficacy and safety of various doses of atorvastatin. Kardiologiia 2007;47(10):51‐3. [MEDLINE: ] - PubMed
Kural 2004 {published data only}
    1. Kural BV, Orem C, Uydu HA, Alver A, Orem A. The effects of lipid‐lowering therapy on paraoxonase activities and their relationships with the oxidant‐antioxidant system in patients with dyslipidemia. Coronary Artery Disease 2004;15(15):277‐83. [MEDLINE: ] - PubMed
Labios 2005 {published data only}
    1. Labios M, Martinez M, Gabriel F, Guiral V, Martinez E, Aznar J. Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry. Thrombosis Research 2005;115(4):263‐70. [MEDLINE: ] - PubMed
Lavallee 2009 {published data only}
    1. Lavallee PC, Labreuche J, Gongora‐Rivera F, Jaramillo A, Brenner D, Klein IF, et al. Placebo‐controlled trial of high‐dose atorvastatin in patients with severe cerebral small vessel disease. Stroke 2009;40(5):1721‐8. [MEDLINE: ] - PubMed
Lawrence 2004 {published data only}
    1. Lawrence JM. Reid J, Taylor GJ, Stirling C, Reckless JP. The effect of high dose atorvastatin therapy on lipids and lipoprotein subfractions in overweight patients with type 2 diabetes. Atherosclerosis 2004;174(1):141‐9. [MEDLINE: ] - PubMed
LCP‐AtorFen 2009 {published data only}
    1. Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M. Efficacy and tolerability of atorvastatin/fenofibrate fixed‐dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12‐week, multicenter, double‐blind, randomized, parallel‐group study. Clinical Therapeutics 2009;31(12):2824‐38. [EMBASE: 2010047966] - PubMed
    1. Davidson, MH, Rooney M, Drucker J, Griffin HE, Beckert M. Atorvastatin/fenofibrate 40/100 mg fixed‐dose combination tablet (LCP‐AtorFen 40/100 mg) offers improved efficacy over 40 mg atorvastatin and higher dose 145 mg fenofibrate in patients with dyslipidemia. Circulation 2008;118 Suppl 2(18):S1139. [PREV200900200229]
Lee 2007 {published data only}
    1. Lee SH, Chung N, Kwan J, Kim DI, Kim WH, Kim CJ, et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8‐week, multicenter, randomized, open‐label, dose‐titration study in Korean patients with hypercholesterolemia. Clinical Therapeutics 2007;29(11):2365‐73. [MEDLINE: ] - PubMed
Lee 2011 {published data only}
    1. Lee SH, Kang SM, Park S, Jang Y, Chung N, Choi D. The effects of statin monotherapy and low‐dose statin/ezetimibe on lipoprotein‐associated phospholipase A2. Clinical Cardiology 2011;34(2):108‐12. [MEDLINE: ] - PMC - PubMed
Lee 2012 {published data only}
    1. Lee SH, Park S, Kang SM, Jang Y, Chung N, Choi D. Effect of atorvastatin monotherapy and low‐dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipidemia. Journal of Cardiovascular Pharmacology & Therapeutics 2012;17(1):65‐71. [MEDLINE: ] - PubMed
Lee 2013 {published data only}
    1. Lee JH, Kang HJ, Kim HS, Sohn DW, Oh BH, Park YB. Effects of ezetimibe/simvastatin 10/20 mg vs. atorvastatin 20 mg on apolipoprotein B/apolipoprotein A1 in Korean patients with type 2 diabetes mellitus: results of a randomized controlled trial. American Journal of Cardiovascular Drugs 2013;13(5):343‐51. [EMBASE: 2013633599] - PubMed
Lemieux 2003 {published data only}
    1. Lemieux I, Salomon H, Despres JP. Contribution of apo CIII reduction to the greater effect of 12‐week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients. Annals of Medicine 2003;35(6):442‐8. [MEDLINE: ] - PubMed
Leung 2002 {published data only}
    1. Leung AWS, Tam KM, Chiu CS. An open‐label, uncontrolled, prospective study of the effects of atorvastatin 10 mg on low‐density lipoprotein cholesterol levels in Chinese adults with coronary artery disease and hypercholesterolemia. Current Therapeutic Research 2002;63(6):399‐408. [EMBASE: 2002283535]
Li 2010 {published data only}
    1. Li J, Sun YM, Wang LF, Li ZQ, Pan W, Cao HY, et al. Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with coronary heart disease. Clinical Cardiology 2010;33(4):222‐7. [MEDLINE: ] - PMC - PubMed
Lins 2004 {published data only}
    1. Lins RL, Carpentier YA, Clinical Investigators Study Group. Plasma lipids and lipoproteins during atorvastatin (atvs) up‐titration in hemodialysis patients with hyperlipidemia: a placebo‐controlled study [abstract]. Nephrology Dialysis Transplantation 2002;17 Suppl 1:124. [CENTRAL: CN‐00509325]
    1. Lins RL, Matthys KE, Billiouw JM, Dratwa M, Dupont P, Lameire NH, et al. Lipid and apoprotein changes during atorvastatin up‐titration in hemodialysis patients with hypercholesterolemia: a placebo‐controlled study. Clinical Nephrology 2004;62(4):287‐94. [MEDLINE: ] - PubMed
Llaverias 2008 {published data only}
    1. Llaverias G, Pou J, Ros E, Zambon D, Cofan M, Sanchez A, et al. Monocyte gene‐expression profile in men with familial combined hyperlipidemia and its modification by atorvastatin treatment. Pharmacogenomics 2008;9(8):1035‐54. [EMBASE: 2008403034] - PubMed
Loughrey 2013 {published data only}
    1. Loughrey BV, McGinty A, Young IS, McCance DR, Powell LA. Increased circulating CC chemokine levels in the metabolic syndrome are reduced by low‐dose atorvastatin treatment: evidence from a randomized controlled trial. Clinical Endocrinology 2013;79(6):800‐6. [EMBASE: 2013713441] - PubMed
LUNAR 2012 {published data only}
    1. Ballantyne CM, Pitt B, Loscalzo J, Cain VA, Raichlen JS. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial). American Journal of Cardiology 2013;111(4):506‐9. [MEDLINE: ] - PubMed
    1. Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J. Comparison of lipid‐modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study). The American Journal of Cardiology 2012;109(9):1239‐46. [MEDLINE: ] - PubMed
Lupattelli 2012 {published data only}
    1. Lupattelli G, Siepi D, Vuono S, Roscini AR, Crisanti F, Covelli D, et al. Cholesterol metabolism differs after statin therapy according to the type of hyperlipemia. Life Sciences 2012;90(21‐22):846‐50. [MEDLINE: ] - PubMed
Ma 2000 {published data only}
    1. Ma P, Hegele R, Yale JF, Schwartz B. CAVEAT: a randomised, double‐blind, parallel group evaluation of cerivastatin 0.4 mg and 0.8 mg compared to atorvastatin 10 mg and 20 mg once daily in patients with combined (type IIb) dyslipidaemia. British Journal of Cardiology 2000;7(12):780‐6. [EMBASE: 2001009668]
    1. Ma P, Hegele, Yale JF, Schwartz B. CAVEAT: a comparison of cerivastatin 0.4 mg and 0.8 mg with atorvastatin 10 mg and 20 mg in patients with combined (type IIB) dyslipidaemia. Atherosclerosis Supplement 2001;2(2):48. [CENTRAL: CN‐00446513]
Mabuchi 2005 {published data only}
    1. Mabuchi H, Higashikata T, Kawashiri M, Katsuda S, Mizuno M, Nohara A, et al. Reduction of serum ubiquinol‐10 and ubiquinone‐10 levels by atorvastatin in hypercholesterolemic patients. Journal of Atherosclerosis & Thrombosis 2005;12(2):111‐9. [MEDLINE: ] - PubMed
Mabuchi 2007 {published data only}
    1. Mabuchi H, Nohara A, Kobayashi J, Kawashiri MA, Katsuda S, Inazu A, et al. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double‐blind study. Atherosclerosis 2007;195(2):e182‐9. [MEDLINE: ] - PubMed
Macin 2005 {published data only}
    1. Macin SM, Perna ER, Farias EF, Franciosi V, Cialzeta JR, Brizuela M, et al. Atorvastatin has an important acute anti‐inflammatory effect in patients with acute coronary syndrome: results of a randomized, double‐blind, placebo‐controlled study. American Heart Journal 2005;149(3):451‐7. [MEDLINE: ] - PubMed
Magen 2004 {published data only}
    1. Magen E, Viskoper R, Mishal J, Priluk R, Berezovsky A, Laszt A, et al. Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control. Israel Medical Association Journal 2004;6(12):742‐6. [MEDLINE: ] - PubMed
Majima 2007 {published data only}
    1. Majima T, Komatsu Y, Fukao A, Ninomiya K, Matsumura T, Nakao K. Short‐term effects of atorvastatin on bone turnover in male patients with hypercholesterolemia. Endocrine Journal 2007;54(1):145‐51. [MEDLINE: ] - PubMed
Maki 2011 {published data only}
    1. Maki KC, Bays HE, Dicklin MR, Johnson SL, Shabbout M. Effects of prescription omega‐3‐acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein‐associated phospholipase A2 mass in men and women with mixed dyslipidemia. Journal of Clinical Lipidology 2011;5(6):483‐92. [MEDLINE: ] - PubMed
Mandosi 2010 {published data only}
    1. Mandosi E, Fallarino M, Gatti A, Carnovale A, Rossetti M, Lococo E, et al. Atorvastatin down regulates monocyte CD36 expression, nuclear NFB and TNFalpha levels in type 2 diabetes. Journal of Atherosclerosis and Thrombosis 2010;17(6):539‐45. [EMBASE: 2010396113] - PubMed
Manuel‐Y‐Keenoy 2004 {published data only}
    1. Manuel‐Y‐Keenoy B, Vinckx M, Vertommen J, Gaal L, Leeuw I. Impact of Vitamin E supplementation on lipoprotein peroxidation and composition in Type 1 diabetic patients treated with Atorvastatin. Atherosclerosis 2004;175(2):369‐76. [MEDLINE: ] - PubMed
Marais 1997 {published data only}
    1. Marais AD, Firth JC, Bateman ME, Byrnes P, Martens C, Mountney J. Atorvastatin: an effective lipid‐modifying agent in familial hypercholesterolemia. Arteriosclerosis, Thrombosis and Vascular Biology 1997;17(8):1527‐31. [MEDLINE: ] - PubMed
Marchesi 2000 {published data only}
    1. Marchesi S, Lupattelli G, Siepi D, Schillaci G, Vaudo G, Roscini AR, et al. Short‐term atorvastatin treatment improves endothelial function in hypercholesterolemic women. Journal of Cardiovascular Pharmacology 2000;36(5):617‐21. [MEDLINE: ] - PubMed
Marketou 2006 {published data only}
    1. Marketou ME, Zacharis EA, Nikitovic D, Ganotakis ES, Parthenakis FI, Maliaraki N, et al. Early effects of simvastatin versus atorvastatin on oxidative stress and pro‐inflammatory cytokines in hyperlipidemic subjects. Angiology 2006;57(2):211‐8. [MEDLINE: ] - PubMed
McInnes 2014 {published data only}
    1. McInnes IB, Kim HY, Lee SH, Mandel D, Song YW, Connell CA, et al. Open‐label tofacitinib and double‐blind atorvastatin in rheumatoid arthritis patients: a randomised study. Annals of the Rheumatic Diseases 2014;73(1):124‐31. [MEDLINE: ] - PubMed
McKenney 1998 {published data only}
    1. McKenney J, McCormick L. The effect of atorvastatin and niacin on lipoprotein subclasses in patients with mixed hyperlipidemia. Atherosclerosis 1997;134:58. [CENTRAL: CN‐00446694]
    1. McKenney JM, McCormack LS, Weiss S, Koren M, Kafonek S, Black DM. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. American Journal of Medicine 1998;104(2):137‐43. [MEDLINE: ] - PubMed
MERCURY I 2004 {published data only}
    1. Cheung RC, Morrell JM, Kallend D, Watkins C, Schuster H. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study. International Journal of Cardiology 2005;100(2):309‐16. [MEDLINE: ] - PubMed
    1. Insull W. Treatment of hypercholesterolemia in patients with the metabolic syndrome: how do various statins compare?. Nature Clinical Practice Cardiovascular Medicine 2006;3(3):134‐5. [EMBASE: 2006101984]
    1. Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM, et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. American Heart Journal 2004;147(4):705‐13. [MEDLINE: ] - PubMed
    1. Schuster H, Palmer MK, Ditmarsch M. The MERCURY I open‐label extension study ‐ subgroup analysis in patients with diabetes. British Journal of Diabetes and Vascular Disease 2008;8(3):142‐7. [EMBASE: 2008340601]
    1. Stender S, Schuster H, Barter P, Watkins C, Kallend D, MERCURY I Study Group. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes, Obesity & Metabolism 2004;7(4):430‐8. [MEDLINE: ] - PubMed
MERCURY II 2006 {published data only}
    1. AstraZeneca. An Open‐label, Randomized, Multi‐center, Phase IIIb, Parallel Group Switching Study to Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin with Rosuvastatin in High Risk Subjects with Type IIa and IIb Hypercholesterolemia (MERCURY II). Protocol No. D3560C00068 (4522IL/0068) 2004.
    1. Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, et al. Achieving LDL cholesterol, non‐HDL cholesterol, and apolipoprotein B target levels in high‐risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. American Heart Journal 2006;151(5):975.e1‐9. [MEDLINE: ] - PubMed
    1. Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low‐density lipoprotein cholesterol and non‐high‐density lipoprotein cholesterol targets in high‐risk patients ‐ The MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY II) trial. Journal of the American College of Cardiology 2008;52(8):626‐32. [DOI: 10.1016/j.jacc.2008.04.052] - DOI - PubMed
Milionis 2003 {published data only}
    1. Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. American Heart Journal 2004;148(4):635‐40. [CENTRAL: CN‐00504472] - PubMed
Milionis 2004 {published data only}
    1. Milionis H, Papkostas J, Kakafika A, Chasiotis G, Seferiadis K, Elisaf MS. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. Journal of Clinical Pharmacology 2003;43(8):825‐30. [MEDLINE: ] - PubMed
Mirdamadi 2008 {published data only}
    1. Mirdamadi HZ, Sztanek F, Derdak Z, Seres I, Harangi M, Paragh G, et al. The human paraoxonase‐1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. British Journal of Clinical Pharmacology 2008;66(3):366‐74. [MEDLINE: ] - PMC - PubMed
MODEST 2009 {published data only}
    1. Kanat M, Serin E, Tunckale A, Yildiz O, Sahin S, Bolayirli M, et al. A multi‐center, open label, crossover designed prospective study evaluating the effects of lipid lowering treatment on steroid synthesis in patients with Type 2 diabetes (MODEST Study). Journal of Endocrinological Investigation 2009;32(10):852‐6. [MEDLINE: ] - PubMed
    1. Kanat M, Yildiz O, Tunckale A, Ceyhan BO, Karagoz Y, Altuntafl Y, et al. Intensive lipid reduction and proinflammatory markers in the MODEST study. Turkish Journal of Endocrinology and Metabolism 2010;14(2):31‐4. [EMBASE: 2010630338]
Monteiro 2008 {published data only}
    1. Monteiro CMC, Oliveira L, Izar MCO, Santos AO, Povoa RMS, Fischer SM, et al. Early effects of lipid lowering treatment in subjects with metabolic syndrome and acute coronary syndromes. International Journal of Atherosclerosis 2008;3(2):93‐9. [EMBASE: 2010215110]
Mori 2013 {published data only}
    1. Mori H, Okada Y, Tanaka Y. Effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia. Diabetology International 2013;4(2):117‐25. [EMBASE: 2013457978]
Morishita 2001 {published data only}
    1. Morishita E, Minami S, Ishino C, Kanno M, Uotani C, Asakura H, et al. Atorvastatin reduces plasma levels of factor VII activity and factor VII antigen in patients with hyperlipidemia. Journal of Atherosclerosis and Thrombosis 2001;9(1):72‐8. [MEDLINE: ] - PubMed
Mullen 2000 {published data only}
    1. Mullen MJ, Wright D, Donald AE, Thorne S, Thomson H, Deanfield JE. Atorvastatin but not L‐arginine improves endothelial function in type I diabetes mellitus: a double‐blind study. Journal of the American College of Cardiology 2000;36(2):410‐6. [MEDLINE: ] - PubMed
Murrow 2012 {published data only}
    1. Murrow JR, Sher S, Au S, Uphoff I, Patel R, Porkert M, et al. The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin. Journal of Clinical Lipidology 2012;6(1):42‐9. [MEDLINE: ] - PubMed
Muscari 2001 {published data only}
    1. Muscari A, Bastagi L, Poggiopollini G, Tomassetti V, Massarelli G, Boni P, et al. Short term effect of atorvastatin and vitamin E on serum levels of C3, a sensitive marker of the risk of myocardial infarction in men. Cardiovascular Drugs & Therapy 2001;15(5):453‐8. [MEDLINE: ] - PubMed
Nagila 2009 {published data only}
    1. Nagila A, Permpongpaiboon T, Tantrarongroj S, Porapakkham P, Chinwattana K, Deakin S, et al. Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status. Pharmacological Reports: PR 2009;61(5):892‐8. [MEDLINE: ] - PubMed
Naoumova 1996 {published data only}
    1. Naoumova RP, Marais AD, Mountney J, Firth JC, Rendell NB, Taylor GW, et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG‐CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis 1996;149(2):203‐13. [MEDLINE: ] - PubMed
Naoumova 1997 {published data only}
    1. Naoumova RP, Dunn S, Rallidis L, Abu‐Muhana O, Neuwirth C, Rendell NB, et al. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. Journal of Lipid Research 1997;38(7):1496‐500. [MEDLINE: ] - PubMed
Naoumova 2003 {published data only}
    1. Naoumova RP, Patel DD, O'Neill FH, Thompson GR, Knight BL. Treatment with atorvastatin alters interleukin‐12 and ‐10 gene expression. European Journal of Clinical Investigation 2003;33(1):88‐91. [EMBASE: 2003018849] - PubMed
NASDAC 2005 {published data only}
    1. Jones PH, McKenney JM, Karalis DG, Downey J. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. American Heart Journal 2005;149(1):e1. [MEDLINE: ] - PubMed
    1. Karalis DG, Ishisaka DY, Luo D, Ntanios F, Wun CC. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia. American Journal of Cardiology 2007;100(3):445‐9. [MEDLINE: ] - PubMed
Nawrocki 1995 {published data only}
    1. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG‐CoA reductase inhibitor. Perfusion 1996;9(3):109‐14. [IDS Number: UM602] - PubMed
    1. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, et al. Reduction of LDL‐cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG‐CoA reductase inhibitor. Arterosclerosis, Thrombosis & Vascular Biology 1995;15(5):678‐82. [MEDLINE: ] - PubMed
Neil 1999 {published data only}
    1. Neil H, Fowler G, Patel H, Eminton Z, Maton S. An assessment of the efficacy of atorvastatin in achieving LDL cholesterol target levels in patients with coronary heart disease: a general practice study. International Journal of Clinical Practice 1999;53(6):422‐6. [MEDLINE: ] - PubMed
Nordøy 2001 {published data only}
    1. Nordøy A, Hansen JB, Brox J, Svensson B. Effects of atorvastatin and omega‐3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. Nutrition Metabolism & Cardiovascular Diseases 2001;11(1):7‐16. [MEDLINE: ] - PubMed
Nozue 2008 {published data only}
    1. Nozue T, Michishita I, Ito Y, Hirano T, Nozue T, Michishita I, et al. Effects of statin on small dense low‐density lipoprotein cholesterol and remnant‐like particle cholesterol in heterozygous familial hypercholesterolemia. Journal of Atherosclerosis & Thrombosis 2008;15(3):146‐53. [MEDLINE: ] - PubMed
Okopien 2004 {published data only}
    1. Okopien B, Krysiak R, Herman ZS. Effect of monthly atorvastatin treatment on hemostasis. International Journal of Clinical Pharmacology & Therapeutics 2004;42(11):589‐93. [MEDLINE: ] - PubMed
Okopien 2005 {published data only}
    1. Okopien B, Krysiak R, Haberka M, Herman ZS. Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein‐1 release in patients with primary mixed dyslipidemia. Journal of Cardiovascular Pharmacology 2005;45(4):314‐20. [MEDLINE: ] - PubMed
Olsson 2001 {published data only}
    1. Astrazeneca. A Randomised, Parallel‐Group Dose‐Response Study with the HMG‐CoA Reductase Inhibitor ZD4522 and Atorvastatin in Subjects with Primary Hypercholesterolaemia. Protocol No. 4522IL/0008 2000.
    1. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low‐density lipoprotein cholesterol in patients with hypercholesterolemia. American Journal of Cardiology 2001;88(5):504‐8. [MEDLINE: ] - PubMed
    1. Pears JS, Olsson AG, Caplan RJ, McKellar J, Raza A. Dose‐ranging study of the HMG‐CoA reductase inhibitor ZD4522 in patients with primary hypercholesterolemia. Canadian Journal of Cardiology 2000;16(Supplement F):196F. [0828‐282X ER]
Olsson 2002 {published data only}
    1. AstraZeneca. A randomised, double‐blind, multinational, multicentre trial to compare the short‐term and long‐term efficacy and safety of ZD4522 and atorvastatin in the treatment of subjects with hypercholesterolaemia (4522IL/0026). Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Biostatistics 1999‐2000:25‐33. [NDA 21‐366]
    1. Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. American Journal of Cardiology 2003;91 Suppl 5A:3C‐10C. [MEDLINE: ] - PubMed
    1. Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. American Heart Journal 2002;144(6):1044‐51. [MEDLINE: ] - PubMed
Ong 2011 {published data only}
    1. Ong LM, Punithavathi N, Lena YLL, Mahanim O, Leekha S. Long term efficacy and safety of a generic atorvastatin in usual clinical care setting. Medical Journal of Malaysia 2011;66(3):214‐9. - PubMed
Ooi 1997 {published data only}
    1. Ooi TC, Heinonen T, Alaupovic P, Davignon J, Leiter L, Lupien PJ, et al. Efficacy and safety of a new hydroxymethylglutaryl‐coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate. Arteriosclerosis Thrombosis and Vascular Biology 1997;17(9):1793‐9. [MEDLINE: ] - PubMed
Oranje 2001 {published data only}
    1. Oranje WA, Sels JPJE, Rondas‐Colbers GJWM, Lemmens PJMR, Wolffenbuttel BHR. Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients. Clinica Chimica Acta 2001;311(2):91‐4. [MEDLINE: ] - PubMed
Orem 2002 {published data only}
    1. Orem C, Orem A, Calapoglu M, Baykan M, Uydu HA, Erdol C. Plasma fibronectin level and its relationships with lipids, lipoproteins and C‐reactive protein in patients with dyslipidaemia during lipid‐lowering therapy. Acta Cardiologica 2002;57(6):421‐5. [MEDLINE: ] - PubMed
Orr 2009 {published data only}
    1. Orr JS, Dengo AL, Rivero JM, Davy KP. Arterial destiffening with atorvastatin in overweight and obese middle‐aged and older adults. Hypertension 2009;54(4):763‐8. [MEDLINE: ] - PubMed
Ozerkan 2006 {published data only}
    1. Ozerkan F, Ozdogan O, Zoghi M, Nalbantgil S, Yavuzgil O, Remzi Onder M. Effects of atorvastatin 10 mg/d on insulin resistance: a 12‐week, open‐label study in hyperlipidemic patients. Current Therapeutic Research Clinical and Experimental 2006;67(1):44‐54. [EMBASE: 2006272912] - PMC - PubMed
Ozsoy 2003 {published data only}
    1. Ozsoy RC, Kastelein JJP, Arisz L, Koopman MG. Atorvastatin and the dyslipidemia of early renal failure. Atherosclerosis 2003;166(1):187‐94. [MEDLINE: ] - PubMed
Pacanowski 2008 {published data only}
    1. Pacanowski MA, Frye RF, Enogieru O, Schofield RS, Zineh I. Plasma coenzyme Q10 predicts lipid‐lowering response to high‐dose atorvastatin. Journal of Clinical Lipidology 2008;2(4):289‐97. [EMBASE: 2008370721] - PMC - PubMed
Paiva 2005 {published data only}
    1. Paiva H, Laasko J, Lehtimaki T, Isomustajarvi M, Ruokonene I, Laaksonen R. Effect of high‐dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. Journal of Cardiovascular Pharmacology 2003;41(2):219‐22. [MEDLINE: ] - PubMed
    1. Paiva H, Thelen KM, Coster R, Smet J, Paepe B, Mattila KM, et al. High‐dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clinical Pharmacology & Therapeutics 2005;78(1):60‐8. [MEDLINE: ] - PubMed
PAPAGO‐T 2013 {published data only}
    1. Liu PY, Lin LY, Lin HJ, Hsia CH, Hung YR, Yeh HI, et al. Pitavastatin and Atorvastatin double‐blind randomized comPArative study among hiGh‐risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO‐T Study). PLoS ONE [Electronic Resource] 2013;8(10):e76298. [EMBASE: 2013618552] - PMC - PubMed
Papathanasiou 2008 {published data only}
    1. Papathanasiou AI, Lourida ES, Tsironis LD, Goudevenos JA, Tselepis AD. Short‐ and long‐term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes. Role of the lipoprotein‐associated phospholipase A2 and the effect of atorvastatin treatment. Atherosclerosis 2008;196(1):289‐97. [MEDLINE: ] - PubMed
Parhofer 2000 {published data only}
    1. Parhofer KG, Hugh P, Barrett R, Schwandt P. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemic subjects. Journal of Clinical Endocrinology & Metabolism 2000;85(11):4224‐30. [MEDLINE: ] - PubMed
Parhofer 2003 {published data only}
    1. Parhofer KG, Laubach E, Barrett PH. Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. Journal of Lipid Research 2003;44(6):1192‐8. [MEDLINE: ] - PubMed
Park 2010 {published data only}
    1. Park JS, Kim YJ, Choi JY, Kim YN, Hong TJ, Kim DS, et al. Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia. The Korean Journal of Internal Medicine 2010;25(1):27‐35. [MEDLINE: ] - PMC - PubMed
Pfizer Inc 16 {unpublished data only}
    1. Pfizer Inc. Phase 2, multi‐center, double‐blind, placebo‐controlled, randomized, parallel group, dose response study of the safety and efficacy of CP‐529,414 combination with open‐label atorvastatin once daily (QD) for 12 weeks in subjects with hypercholesterolemia and without overt cardiovascular disease. Protocol No. A5091049 2005.
Pfizer Inc 19 {unpublished data only}
    1. Pfizer Inc. To compare the effects on lipoprotein fractions and safety of atorvastatin with that of fenofibrate. Protocol 981‐55 1998. [NDA: 20‐702S003]
Pirkova 2007 {published data only}
    1. Pirkova AA, Samoilova EV, Ameliushkina VA, Kaminnyi AI, Titov VN, Prokazova NV, et al. Effect of atorvastatin therapy on the level of secretory phospholipase A2 group IIA and on the modification of low density lipoproteins in patients with ischemic heart disease. Kardiologiia 2007;47(4):37‐40. [MEDLINE: ] - PubMed
PITCH 2012 {published data only}
    1. Han KH, Rha SW, Kang HJ, Bae JW, Choi BJ, Choi SY, et al. Evaluation of short‐term safety and efficacy of HMG‐CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (pitavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage). Journal of Clinical Lipidology 2012;6(4):340‐51. [MEDLINE: ] - PubMed
Plakogiannis 2002 {published data only}
    1. Plakogiannis R. The chronologic effects of atorvastatin: morning versus evening administration in hyperlipidemic adults, 2002. proquest.umi.com/pqdweb?did=726006791&sid=1&Fmt=2&clientId=6... (accessed 5 November 2012). [ProQuest document ID: 726006791]
    1. Plakogiannis R, Cohen H, Taft D. Effects of morning versus evening administration of atorvastatin in patients with hyperlipidemia. American Journal of Health‐System Pharmacy 2005;62(23):2491‐4. [MEDLINE: ] - PubMed
Pontrelli 2002 {published data only}
    1. Pontrelli L, Parris W, Adeli K, Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low‐density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 2002;51(3):334‐42. [MEDLINE: ] - PubMed
PRAT 2013 {published data only}
    1. Sasaki J, Otonari T, Uchida Y, Ikeda Y, Biro S, Kono S, et al. Effects of pravastatin and atorvastatin on HDL cholesterol and glucose metabolism in patients with dyslipidemia and glucose intolerance: the PRAT study. Journal of Atherosclerosis & Thrombosis 2013;20(4):368‐79. [MEDLINE: ] - PubMed
Puato 2010 {published data only}
    1. Puato M, Faggin E, Rattazzi M, Zambon A, Cipollone F, Grego F, et al. Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a nonstatin‐based regimen in patients undergoing carotid endarterectomy 20195400. Stroke 2010;41(6):1163‐8. [MEDLINE: ] - PubMed
Puccetti 2002 {published data only}
    1. Puccetti L, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, et al. Time‐dependent effect of statins on platelet function in hypercholesterolaemia. European Journal of Clinical Investigation 2002;32(12):901‐8. [MEDLINE: ] - PubMed
Puccetti 2005 {published data only}
    1. Puccetti L, Pasqui AL, Pastorelli M, Ciani F, Palazzuoli A, Gioffre W, et al. 3'UTR/T polymorphism of lectin‐like oxidized low‐density lipoprotein receptor‐1 (LOX‐1) is associated with modified anti‐platelet activity of atorvastatin in hypercholesterolemic subjects. Atherosclerosis 2005;183(2):322‐8. [MEDLINE: ] - PubMed
PULSAR 2006 {published data only}
    1. Anonymous. First open‐label study to compare rosuvastatin to atorvastatin in high‐risk patients shows benefits of effective statin starting dose. Cardiovascular Journal of Africa 2007;18(1):60. [EMBASE: 2008249348]
    1. AstraZeneca. A 6‐week Open‐label, Randomised, Multicentre, Phase IIIb, Parallel‐group Study to Compare the Efficacy and Safety of Rosuvastatin (10 mg) with Atorvastatin (20 mg) in Subjects with Hypercholesterolaemia and Either a History of Coronary Heart Disease (CHD) or Clinical Evidence of Atherosclerosis or a CHD Risk Equivalent (10‐year Risk Score of >20%). Protocol No. 4522IL/0102 (D3569C00001) 31 2005.
    1. Clearfield MB, Amerena J, Bassand JP, García HRH, Miller SS, Sosef FFM, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high‐risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials 2006;7(35):not applicable. [EMBASE: 2007065270] - PMC - PubMed
Puurunen 2013 {published data only}
    1. Puurunen J, Piltonen T, Puukka K, Ruokonen A, Savolainen MJ, Bloigu R, et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double‐blind, placebo‐controlled study. Journal of Clinical Endocrinology & Metabolism 2013;98(12):4798‐807. [EMBASE: 2013778908] - PubMed
Qi 2013 {published data only}
    1. Qi Y, Liu J, Ma C, Wang W, Liu X, Wang M, et al. Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary heart disease. Journal of Lipid Research 2013;54(11):3189‐97. [EMBASE: 2013670884] - PMC - PubMed
RADAR 2005 {published data only}
    1. Bergheanu SC, Reijmers T, Zwinderman AH, Bobeldijk I, Ramaker R, Liem AH, et al. Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Current Medical Research & Opinion 2008;24(9):2477‐87. [MEDLINE: ] - PubMed
    1. Bergheanu SC, Tol A, Dallinga‐Thie GM, Liem A, Dunselman PH, Bom JG, et al. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase‐1 activity in men with established cardiovascular disease and a low HDL‐cholesterol. Current Medical Research & Opinion 2007;23(9):2235‐40. [MEDLINE: ] - PubMed
    1. Jukema JW, Liem AH, Dunselman PH, Sloot JA, Lok DJ, Zwinderman AH. LDL‐C/HDL‐C ratio in subjects with cardiovascular disease and a low HDL‐C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Current Medical Research & Opinion 2005;21(11):1865‐74. [MEDLINE: ] - PubMed
    1. Karalis IK, Bergheanu SC, Wolterbeek R, Dallinga‐Thie GM, Hattori H, Tol A, et al. Effect of increasing doses of rosuvastatin and atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters. Current Medical Research and Opinion 2010; Vol. 26, issue 10:2301‐13. [MEDLINE: ] - PubMed
Raison 2002 {published data only}
    1. Raison J, Rudnichi A, Safar ME. Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study. Journal of Human Hypertension 2002;16(10):705‐10. [MEDLINE: ] - PubMed
Reinares 2002 {published data only}
    1. Reinares L, Figueredo A, Rueda A, Pontes JC, Rodriguez A, Ruiz‐Yague M, et al. Atorvastatin reduces expression of the CCR2 and MAC‐1 receptors on monocytes, and plasma levels of monocyte chemoattractant protein‐1 and C‐reactive protein, in patients with coronary heart disease. Clinical Drug Investigation 2002;22(1):1‐8. [EMBASE: 2002067878]
Reiter 2005 {published data only}
    1. Reiter M, Wirth S, Pourazim A, Baghestanian M, Minar E, Bucek RA. Statin therapy has no significant effect on skin tissue cholesterol: results from a prospective randomized trial. Clinical Chemistry 2005;51(1):252‐4. [MEDLINE: ] - PubMed
RESPOND 2007 {published data only}
    1. Pfizer Inc. A Multi‐National, Prospective Randomized Double‐Blind, Multi‐Center, Placebo‐Controlled Study to Evaluate Efficacy and Safety of a Fixed Combination Therapy of Amlodipine and Atorvastatin in the Treatment of Concurrent Hypertension and Hyperlipidemia ‐ the RESPOND Trial. Protocol No. A3841003 2003.
    1. Preston RA, Harvey P, Herfert O, Dykstra G, Jukema JW, Sun F, et al. A randomized, placebo‐controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of co‐administered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the RESPOND trial. Journal of Clinical Pharmacology 2007;47(12):1555‐69. [MEDLINE: ] - PubMed
Rodrigues 2013 {published data only}
    1. Rodrigues AC, Sobrino B, Genvigir FD, Willrich MA, Arazi SS, Dorea EL, et al. Genetic variants in genes related to lipid metabolism and atherosclerosis, dyslipidemia and atorvastatin response. Clinica Chimica Acta 2013;417:8‐11. [MEDLINE: ] - PubMed
Rodriguez‐Roa 2008 {published data only}
    1. Rodriguez‐Roa E, Tellez R, Rodriguez F, Gonzalez M. Comparative evaluation of clinical effectiveness of two atorvastatin formulations in patients with or without cardiovascular disease: a national multicentric study. Revista Latinoamericana de Hipertension 2008;3(4):129‐35. [EMBASE: 2008497379]
ROMEO 2011 {published data only}
    1. NCT00395486. A 6‐week, Randomised, Open‐label, Parallel Group, Multi‐centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Metabolic Syndrome Subjects With Raised LDL‐C. https://clinicaltrials.gov/ct2/show/NCT00395486 (accessed 2 March 2015).
Rosales 2012 {published data only}
    1. Rosales A, Alvear M, Cuevas A, Saavedra N, Zambrano T, Salazar LA. Identification of pharmacogenetic predictors of lipid‐lowering response to atorvastatin in Chilean subjects with hypercholesterolemia. Clinica Chimica Acta 2012;413(3‐4):495‐501. [MEDLINE: ] - PubMed
Rosenson 2009 {published data only}
    1. Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double‐blind, controlled study. Diabetes Care 2009;32(6):1087‐91. [EMBASE: 2009272130] - PMC - PubMed
SAGE 2007 {published data only}
    1. Deedwania P, Stone PH, Bairey Merz CN, Cosin‐Aguilar J, Koylan N, Luo D, et al. Effects of intensive versus moderate lipid‐lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007;115(6):700‐7. [MEDLINE: ] - PubMed
    1. Deedwania PC. Study Assessing Goals in the Elderly Steering Committee and Investigators. Effect of aggressive versus moderate lipid‐lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE). American Heart Journal 2004;148(6):1053‐9. [MEDLINE: ] - PubMed
    1. Pfizer Inc. A Prospective, Randomized, Double‐blind, Multi‐center Study Comparing the Effects of Aggressive Lipid Lowering with Moderate Lipid Lowering on the Reduction of Total Duration of Myocardial Ischema in the Elderly as Measured by Holter Monitoring by Comparing the Maximal Doses of Two Statins: Study Assessing Goals in the Elderly (SAGE). Protocol No. 981‐400‐421‐429 2004.
Sakabe 2004 {published data only}
    1. Sakabe K, Fukuda N, Wakayama K, Nada T, Shinohara H, Tamura Y. Lipid‐altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia. American Journal of Cardiology 2004;94(4):497‐500. [MEDLINE: ] - PubMed
Sakabe 2008a {published data only}
    1. Sakabe K, Fukuda N, Fukuda Y, Wakayama K, Nada T, Morishita S, et al. Gender differences in short‐term effects of atorvastatin on lipid profile, fibrinolytic parameters, and endothelial function. Nutrition Metabolism & Cardiovascular Diseases 2008;18(3):182‐8. [MEDLINE: ] - PubMed
Saklamaz 2005 {published data only}
    1. Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, et al. The beneficial effects of lipid‐lowering drugs beyond lipid‐lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia. Metabolism: Clinical & Experimental 2005;54(5):677‐81. [MEDLINE: ] - PubMed
Sansanayudh 2010 {published data only}
    1. Sansanayudh N, Wongwiwatthananukit S, Putwai P, Dhumma‐Upakorn R. Comparative efficacy and safety of low‐dose pitavastatin versus atorvastatin in patients with hypercholesterolemia. The Annals of Pharmacotherapy 2010;44(3):415‐23. [MEDLINE: ] - PubMed
Sardo 2002 {published data only}
    1. Sardo MA, Castaldo M, Cinquegrani M, Bonaiuto M, Maesano A, Versace A, et al. Effects of atorvastatin treatment on sICAM‐1 and plasma nitric oxide levels in hypercholesterolemic subjects. Clinical and Applied Thrombosis/Hemostasis 2002;8(3):257‐63. [MEDLINE: ] - PubMed
Sari 2007 {published data only}
    1. Sari R, Eray E. The effect of atorvastatin treatment on insulin resistance, leptin, and highly sensitive C‐reactive protein in hypercholesterolemic patients. Endocrinologist 2007;17(6):315‐7. [EMBASE: 2007624268]
Sasaki 2008 {published data only}
    1. Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, et al. A 52‐week, randomized, open‐label, parallel‐group comparison of the tolerability and effects of pitavastatin and atorvastatin on high‐density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low‐density lipoprotein cholesterol and glucose intolerance. Clinical Therapeutics 2008;30(6):1089‐101. [MEDLINE: ] - PubMed
Sathyapalan 2009 {published data only}
    1. Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double‐blind placebo‐controlled study. Journal of Clinical Endocrinology & Metabolism 2009;94(1):103‐8. [MEDLINE: ] - PubMed
Save 2006 {published data only}
    1. Save V, Patil N, Moulik N, Rajadhyaksha G. Effect of atorvastatin on type 2 diabetic dyslipidemia. Journal of Cardiovascular Pharmacology & Therapeutics 2006;11(4):262‐70. [MEDLINE: ] - PubMed
Schneck 2003 {published data only}
    1. Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. American Journal of Cardiology 2003;91(1):33‐41. [MEDLINE: ] - PubMed
Schneider 2004 {published data only}
    1. Schneider JG, Eynatten M, Parhofer KG, Volkmer JE, Schiekofer S, Hamann A, et al. Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. Atherosclerosis 2004;175(2):325‐31. [MEDLINE: ] - PubMed
    1. Eynatten M, Liu D, Bluemm A, Schuster T, Baumann M, Lutz J, et al. Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes. Clinical Endocrinology 2009;71(1):27‐32. [EMBASE: 2009287090] - PubMed
Schrott 1998 {published data only}
    1. Pfizer Inc. Crystalline Form Atorvastatin Dose‐Ranging. Protocol No. 981‐96 1997.
    1. Schrott H, Fereshetian AG, Knopp RH, Bays H, Jones PH, Littlejohn III TW, et al. A multicenter, placebo‐controlled, dose‐ranging study of atorvastatin. Journal of Cardiovascular Pharmacology & Therapeutics 1998;3(2):119‐24. [EMBASE: 1999101186] - PubMed
Schwartz 2004 {published data only}
    1. AstraZeneca. A 24‐Week, Randomized, Double‐Blind, Multicenter Trial to Evaluate the Efficacy and Safety of Starting and Maximum Doses of ZD4522 and Atorvastatin in the Treatment of High Risk Hypercholesterolemic Subjects (4522IL/0025). Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Biostatistics 1999‐2000:17‐25. [NDA 21‐366]
    1. Schwartz GG, Bolognese MA, Tremblay BP, Caplan R, Hutchinson H, Raza A, et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. American Heart Journal 2004;148(1):e4. [MEDLINE: ] - PubMed
Shabana 2013 {published data only}
    1. Shabana MF, Mishriki AA, Issac MS, Bakhoum SW. Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia. Molecular Diagnosis & Therapy 2013;17(5):299‐309. [EMBASE: 2013633604] - PubMed
Shimabukuro 2011 {published data only}
    1. Shimabukuro M, Higa M, Tanaka H, Shimabukuro T, Yamakawa K, Masuzaki H. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus. Diabetic Medicine: a Journal of the British Diabetic Association 2011;28(7):856‐64. [MEDLINE: ] - PubMed
Shishehbor 2003 {published data only}
    1. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003;289(13):1675‐80. [MEDLINE: ] - PubMed
SHUKRA 2008 {unpublished data only}
    1. AstraZeneca. A Phase IV, 6‐Week, Randomised, Double‐blind, Multicentre, Parallel Group, Comparative Study to Evaluate the Efficacy of Rosuvastatin 5 mg and Atorvastatin 10 mg in UK Asian Subjects with Primary Hypercholesterolaemia SHUKRA ‐ Study of Asian Patients with Hypercholesterolaemia in the UK Rosuvastatin 5 mg versus Atorvastatin 10 mg. Protocol No. D3560L00060 2008.
Simons 1998 {published data only}
    1. Simons LA. Comparison of atorvastatin alone versus simvastatin +/‐ cholestyramine in the management of severe primary hypercholesterolaemia (the six cities study). Australian & New Zealand Journal of Medicine 1998;28(3):327‐33. [MEDLINE: ] - PubMed
Singh 2008 {published data only}
    1. Singh U, Devaraj S, Jialal I, Siegel D. Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. The American Journal of Cardiology 2008;102(3):321‐5. [MEDLINE: ] - PMC - PubMed
Sinski 2009 {published data only}
    1. Sinski M, Lewandowski J, Ciarka A, Bidiuk J, Abramczyk P, Dobosiewicz A, et al. Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension. Kardiologia Polska 2009;67(6):613‐20. [MEDLINE: ] - PubMed
Sirtori 2005 {published data only}
    1. Sirtori CR, Calabresi L, Pisciotta L, Cattin L, Pauciullo P, Montagnani M, et al. Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin. Nutrition Metabolism & Cardiovascular Diseases 2005;15(1):47‐55. [MEDLINE: ] - PubMed
SLIM 2009 {published data only}
    1. Knopp RH, Retzlaff BM, Fish B, Dowdy A, Twaddell B, Nguyen T, et al. The SLIM study: slo‐niacin and atorvastatin treatment of lipoproteins and inflammatory markers in combined hyperlipidemia. Journal of Clinical Lipidology 2009;3(3):167‐78. [EMBASE: 2009284377] - PMC - PubMed
SOLAR 2007 {published data only}
    1. AstraZeneca. A 12‐Week, Randomized, Open‐label, 3‐Arm Parallel‐group, Multicenter, Phase IIIb Study Comparing the Efficacy and Safety of Rosuvastatin with Atorvastatin and Simvastatin Achieving NCEP ATP III LDL‐C Goals in High‐risk Subjects with Hypercholesterolemia in the Managed Care Setting (SOLAR study). Protocol No. D3560L00023 2005.
    1. Insull W Jr, Ghali JK, Hassman DRY, As JW, Gandhi SK, Miller E. Achieving low‐density lipoprotein cholesterol goals in high‐risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Mayo Clinic Proceedings 2007;82(5):543‐50. [MEDLINE: ] - PubMed
    1. Insull W, Ycas J, Miller E. Effect of three statins at starting dose on achieving national LDL‐C goals in hypercholesterolemic patients with or without diabetes in a managed‐care setting. Diabetes 2005;54 Suppl 1:A568. [IDS Number: 931QZ]
Sposito 2003 {published data only}
    1. Sposito AC, Santos RD, Amancio RF, Ramires JA, Chapman MJ, Maranhao RC. Atorvastatin enhances the plasma clearance of chylomicron‐like emulsions in subjects with atherogenic dyslipidemia: relevance to the in vivo metabolism of triglyceride‐rich lipoproteins. Atherosclerosis 2003;166(2):311‐21. [MEDLINE: ] - PubMed
STARSHIP 2006 {published data only}
    1. AstraZeneca. Report on the Randomized Treatment Phase. A 6‐week, Randomized, Open‐Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Hypercholesterolemia in Hispanic Subjects (STARSHIP). Protocol No. D3560L00027 (4522US/0007) 2005.
    1. Lloret R, Ycas J, Stein M, Haffner S, STARSHIP Study Group. Comparison of rosuvastatin versus atorvastatin in Hispanic‐Americans with hypercholesterolemia (from the STARSHIP trial). American Journal of Cardiology 2006;98(6):768‐73. [MEDLINE: ] - PubMed
STELLAR 2003 {published data only}
    1. Ai M, Otokozawa S, Asztalos BF, Nakajima K, Stein E, Jones PH, et al. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low‐density lipoprotein cholesterol levels. The American Journal of Cardiology 2008; Vol. 101, issue 3:315‐8. [MEDLINE: ] - PubMed
    1. AstraZeneca. A 6‐Week, Open‐Label, Dose‐Comparison Study to Evaluate the Safety and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Subjects with Hypercholesterolemia (STELLAR). Protocol No. 4522IL/0065_LTE/D3560C00065 2005.
    1. Asztalos BF, Maulf F, Dallal GE, Stein E, Jones PH, Horvath KV, et al. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high‐density lipoproteins. American Journal of Cardiology 2007;99(5):681‐5. [MEDLINE: ] - PubMed
    1. Barrios V, Lobos J M, Serrano A, Brosa M, Capel M, Alvarez Sanz C. Cost‐effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain. Journal of Medical Economics 2012;15 Suppl 1:45‐54. [CENTRAL: CN‐00858418 NEW] - PubMed
    1. Chong PH, Varner D. Cost‐efficacy analysis of 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase inhibitors based on results of the STELLAR trial: clinical implications for therapeutic selection. Pharmacotherapy 2005;25(2):270‐8. [MEDLINE: ] - PubMed
Stojakovic 2007 {published data only}
    1. Stojakovic T, Putz‐Bankuti C, Fauler G, Scharnagl H, Wagner M, Stadlbauer V, et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007;46(3):776‐84. [MEDLINE: ] - PubMed
SToP AF 2011 {published data only}
    1. Negi S, Shukrullah I, Veledar E, Bloom HL, Jones DP, Dudley SC. Statin therapy for the prevention of atrial fibrillation trial (SToP AF trial). Journal of Cardiovascular Electrophysiology 2011;22(4):414‐9. [MEDLINE: ] - PMC - PubMed
STRENGTH 2008 {published data only}
    1. Voora D, Shah SH, Reed CR, Zhai J, Crosslin DR, Messer C, et al. Pharmacogenetic predictors of statin‐mediated low‐density lipoprotein cholesterol reduction and dose response. Circulation. Cardiovascular Genetics 2008;1(2):100‐6. [MEDLINE: ] - PMC - PubMed
    1. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, et al. The SLCO1B1*5 genetic variant is associated with statin‐induced side effects. Journal of the American College of Cardiology 2009; Vol. 54, issue 17:1609‐16. [MEDLINE: ] - PMC - PubMed
Stulc 2008 {published data only}
    1. Stulc T, Vrablik M, Kasalova Z, Marinov I, Svobodova H, Ceska R. Leukocyte and endothelial adhesion molecules in patients with hypercholesterolemia: the effect of atorvastatin treatment. Physiological Research 2008;57(2):184‐94. [MEDLINE: ] - PubMed
Suleiman 2012 {published data only}
    1. Suleiman M, Koestler C, Lerman A, Lopez‐Jimenez F, Herges R, Hodge D, et al. Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: a double‐blind, placebo‐controlled, randomized trial. Heart Rhythm 2012;9(2):172‐8. [MEDLINE: ] - PubMed
SUPREME 2009 {published data only}
    1. Insull W Jr, Basile JN, Vo AN, Jiang P, Thakkar R, Padley RJ. Efficacy and safety of combination therapy with niacin extended‐release and simvastatin versus atorvastatin in patients with dyslipidemia: the SUPREME Study. Journal of Clinical Lipidology 2009;3(2):109‐18. [EMBASE: 2009130987] - PubMed
    1. Insull W Jr, Toth PP, Superko HR, Thakkar RB, Krause S, Jiang P, et al. Combination of niacin extended‐release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. Vascular Health and Risk Management 2010; Vol. 6:1065‐75. [MEDLINE: ] - PMC - PubMed
Szapary 2004 {published data only}
    1. Szapary L, Horvath B, Marton Z, Alexy T, Kesmarky G, Habon T, et al. Short‐term effect of low‐dose atorvastatin on haemorheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia. CNS Drugs 2004;18(3):165‐72. [MEDLINE: ] - PubMed
Tagle 2000 {published data only}
    1. Tagle M, Salazar A, Gomez L, Alava Y, Bajana W. Clinical observation of the efficacy and safety of atorvastatin in the therapy of patients with hypercholesterolemia [Observacion clinica de la eficacia y seguridad de la administracion de atrovastatina en el tratamiento de pacientes con hipercolesterolemia]. Endocrinologia y Nutricion 2000;47(6):156‐60. [EMBASE: 2000318241]
Takebayashi 2005 {published data only}
    1. Takebayashi K, Matsumoto S, Wakabayashi S, Inukai Y, Matsutomo R, Aso Y, et al. The effect of low‐dose atorvastatin on circulating monocyte chemoattractant protein‐1 in patients with type 2 diabetes complicated by hyperlipidemia. Metabolism: Clinical & Experimental 2005;54(9):1225‐9. [MEDLINE: ] - PubMed
Tan 2002 {published data only}
    1. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS. Atorvastatin lowers C‐reactive protein and improves endothelium‐dependent vasodilation in type 2 diabetes mellitus. Journal of Clinical Endocrinology & Metabolism 2002;87(2):563‐8. [MEDLINE: ] - PubMed
Tanaka 2001 {published data only}
    1. Tanaka A, Yamada N, Saito Y, Kawakami M, Ohashi Y, Akanuma Y. A double‐blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia. Clinica Chimica Acta 2001;312(1‐2):41‐7. [MEDLINE: ] - PubMed
TARGET TANGIBLE 1999 {published data only}
    1. Maerz W, Wollschlaeger H, Klein G, Neiss A, Wehling M. Safety of low‐density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial). American Journal of Cardiology 1999;84(1):7‐13. [MEDLINE: ] - PubMed
    1. Maerz W, Wollschlager H, Klein G, Neiss A, Wehling M. Comparison of the safety of atorvastatin and simvastatin in patients with coronary heart disease ‐ the target tangible trial. Atherosclerosis 1999;144(1):29. [CENTRAL: CN‐00446640] - PubMed
    1. Marz W, Wollschlager H, Klein G, Neiss A, Wehling M. Efficacy and safety of atorvastatin versus simvastatin in type II diabetes patients with coronary heart disease. Diabetologia 1999;42(Supplement 1):A19. [IDS Number: 225CC]
    1. Marz W, Wollschlager H, Klein G, Neiss A, Wehling M. Safety of low‐density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE Trial). Perfusion 1999;12(10):427‐36. [IDS Number: 252QE] - PubMed
    1. Ruof J, Klein G, Marz W, Wollschlager H, Neiss A, Wehling M. Lipid‐lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns. Preventive Medicine 2002;35(1):48‐53. [MEDLINE: ] - PubMed
Tateishi 2011 {published data only}
    1. Tateishi J. Efficacy of three potent statins in patients with hypercholesterolemia who were newly prescribed statins. Therapeutic Research 2011;32(12):1653‐61. [EMBASE: 2012051834]
Tekin 2004 {published data only}
    1. Tekin A, Tekin G, Guzelsoy D, Kaya A, Gurel CV, Yigit Z, et al. Effects of atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease. American Journal of Cardiology 2004;94(2):206‐9. [MEDLINE: ] - PubMed
Tekten 2004 {published data only}
    1. Tekten T, Ceyhan C, Ercan E, Onbasili AO, Turkoglu C. The effect of atorvastatin on platelet function in patients with coronary artery disease. Acta Cardiologica 2004;59(3):311‐5. [MEDLINE: ] - PubMed
Tomas 2004 {published data only}
    1. Tomas JP, Moya JL, Campuzano R, Barrios V, Megias A, Ruiz S, et al. Noninvasive assessment of the effect of atorvastatin on coronary microvasculature and endothelial function in patients with dyslipidemia. Revista Espanola de Cardiologia 2004;57(10):909‐15. [MEDLINE: ] - PubMed
Tousoulis 2005 {published data only}
    1. Tousoulis D, Antoniades C, Vassiliadou C, Toutouza M, Pitsavos C, Tentolouris C, et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. European Journal of Heart Failure 2005;7(7):1126‐32. [MEDLINE: ] - PubMed
Tousoulis 2006 {published data only}
    1. Tousoulis D, Bosinakou E, Kotsopoulou M, Antoniades C, Katsi V, Stefanadis C. Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina. International Journal of Cardiology 2006;106(3):333‐7. [MEDLINE: ] - PubMed
Tousoulis 2011 {published data only}
    1. Tousoulis D, Koniari K, Antoniades C, Papageorgiou N, Miliou A, Noutsou M, et al. Combined effects of atorvastatin and metformin on glucose‐induced variations of inflammatory process in patients with diabetes mellitus. International Journal of Cardiology 2011;149(1):46‐9. [MEDLINE: ] - PubMed
Tsunoda 2011 {published data only}
    1. Tsunoda S. Efficacy and safety of rosuvastatin 2.5 mg and atorvastatin 10 mg in patients with hypercholesterolemia. Therapeutic Research 2011;32(11):1507‐12. [EMBASE: 2011711049]
Undas 2006a {published data only}
    1. Undas A, Brummel‐Ziedins KE, Potaczek DP, Stobierska‐Dzierzek B, Bryniarski L, Szczeklik A, et al. Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy. Journal of Thrombosis & Haemostasis 2006;4(11):2397‐404. [MEDLINE: ] - PubMed
Uydu 2012 {published data only}
    1. Uydu H A, Yildirmis S, Orem C, Calapoglu M, Alver A, Kural B, et al. The effects of atorvastatin therapy on rheological characteristics of erythrocyte membrane, serum lipid profile and oxidative status in patients with dyslipidemia. Journal of Membrane Biology 2012;245(11):697‐705. [MEDLINE: ] - PubMed
Vansant 2001 {published data only}
    1. Vansant G, Mertens A, Muls E. The effect of atorvastatin on postprandial lipidaemia in overweight or obese women homozygous for apo E3. Acta Cardiologica 2001;56(3):149‐54. [MEDLINE: ] - PubMed
VISION 2013 {published data only}
    1. Yoshida H, Shoda T, Yanai H, Ikewaki K, Kurata H, Ito K, et al. Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. Atherosclerosis 2013;226(1):161‐4. [MEDLINE: ] - PubMed
VYTAL 2006 {published data only}
    1. Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis A, Edwards P, et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clinic Proceedings 2006;81(12):1579‐88. [MEDLINE: ] - PubMed
    1. Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis AB, Tipping D, et al. Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia. Diabetes Care 2010; Vol. 33, issue 5:1021‐4. [MEDLINE: ] - PMC - PubMed
    1. Guyton JR, Goldberg RB, Mazzone T, Weinstock RS, Polis A, Rosenberg E, et al. Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes. Journal of Clinical Lipidology 2008;2(1):19‐24. [EMBASE: 2008082220] - PubMed
    1. Merck, Co Inc. Ezetimibe/Simvastatin (Vytorin) versus Atorvastatin in Type 2 Diabetes Patients with Hypercholesterolemia: the VYTAL Study. Merck Protocol Number: 077 2005.
    1. Tomassini JE, Mazzone T, Goldberg RB, Guyton JR, Weinstock RS, Polis A, et al. Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia. Diabetes, Obesity & Metabolism 2009; Vol. 11, issue 9:855‐64. [MEDLINE: ] - PubMed
VYTELD 2010 {published data only}
    1. Foody JM, Brown WV, Zieve F, Adewale AJ, Flaim D, Lowe RS, et al. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults >=65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study). American Journal of Cardiology 2010;106(9):1255‐63. [MEDLINE: ] - PubMed
    1. Yip A, Hegele RA. Lipid modification in the elderly using the combination of a statin and a cholesterol absorption inhibitor: associated included citation for the VYTELD 2010 trial. Expert Opinion on Pharmacotherapy 2011;12(4):675‐8. [MEDLINE: ] - PubMed
VYVA 2005 {published data only}
    1. Abate N, Catapano AL, Ballantyne CM, Davidson MH, Polis A, Smugar SS, et al. Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: results of two subgroup analyses. Journal of Clinical Lipidology 2008;2(2):91‐105. [EMBASE: 2008124668] - PubMed
    1. Ballantyne CM, Abate N, King TR, Yuan Z, Palmisano J, Tershakovec A. Ezetimibe/Simvastatin versus atorvastatin for attainment of apolipoprotein B and C‐reactive protein goals: a VYVA substudy. Journal of the American College of Cardiology 2006;47 Suppl A(4):335A. [IDS Number: 015CV]
    1. Ballantyne CM, Abate N, Yuan Z. Dose‐comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. American Heart Journal 2005;149(5):882. [IDS Number: 932NN] - PubMed
    1. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose‐comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. American Heart Journal 2005;149(3):464‐73. [MEDLINE: ] - PubMed
    1. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Prevention and rehabilitation ‐ dose‐comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. American Heart Journal 2005;149(3):464‐73. [DOI: 10.1016/j.ahj.2004.11.023; IDS Number: 917RV] - DOI - PubMed
Wang 2001 {published data only}
    1. Wang KY, Ting CT. A randomized, double‐blind, placebo‐controlled, 8‐week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL‐cholesterol. Japanese Heart Journal 2001;42(6):725‐38. [MEDLINE: ] - PubMed
Wang 2012 {published data only}
    1. Wang GH, Zhang X, Cao J, Li HT, Yin D, Zhou CJ. Lipid‐lowering efficacy and safety of rosuvastatin calcium in treatment of patients with chronic kidney disease. Guangdong Yixue 2012;33(1):125‐7. [CENTRAL: CN‐00858145 NEW]
WATCH 2001 {published data only}
    1. McPherson R, Angus C, Murray P, Genest J Jr. Efficacy of atorvastatin in achieving national cholesterol education program low‐density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: the Women's Atorvastatin Trial on Cholesterol (WATCH). American Heart Journal 2001;141(6):949‐56. [MEDLINE: ] - PubMed
Wei 2001 {unpublished data only}
    1. Wei L. Clinical features and risk of coronary heart disease in familial hypercholesterolaemia and studies on hypolipidaemic drug treatment in Hong Kong Chinese. DAI‐B 62/01 2001:p. 151. [ProQuest document ID: 728458161]
Welder 2010 {published data only}
    1. Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ, et al. High‐dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. Journal of Lipid Research 2010;51(9):2714‐21. [MEDLINE: ] - PMC - PubMed
Wierzbicki 1998 {published data only}
    1. Wierzbicki AS, Lumb PJ, Semra YK, Crook MA. High‐dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia. Quarterly Journal of Medicine 1998;91(4):291‐4. [MEDLINE: ] - PubMed
Willrich 2008 {published data only}
    1. Genvigir FD, Soares SA, Hirata MH, Willrich MA, Arazi SS, Rebecchi IM, et al. Effects of ABCA1 SNPs, including the C‐105T novel variant, on serum lipids of Brazilian individuals. Clinica Chimica Acta 2008;389(1‐2):79‐86. [MEDLINE: ] - PubMed
    1. Rebecchi IM, Rodrigues AC, Arazi SS, Genvigir FD, Willrich MA, Hirata MH, et al. ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment. Biochemical Pharmacology 2009;77(1):66‐75. [MEDLINE: ] - PubMed
    1. Rodrigues AC, Perin PMS, Purim SG, Silbiger VN, Genvigir FDV, Willrich MAV, et al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388a>G variant is determinant of increased atorvastatin response. International Journal of Molecular Sciences 2011;12(9):5815‐27. [EMBASE: 2011537606] - PMC - PubMed
    1. Willrich MA, Hirata MH, Genvigir FD, Arazi SS, Rebecchi IM, Rodrigues AC, et al. CYP3A53A allele is associated with reduced lowering‐lipid response to atorvastatin in individuals with hypercholesterolemia. Clinica Chimica Acta 2008;398(1‐2):15‐20. [MEDLINE: ] - PubMed
    1. Willrich MA, Rodrigues AC, Cerda A, Genvigir FD, Arazi SS, Dorea EL, et al. Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholesterolemic patients: associated included citation for the Willrich 2008 trial. Clinica Chimica Acta 2013;421:157‐63. [MEDLINE: ] - PubMed
Wu 2002 {published data only}
    1. Wu CC, Sy R, Tanphaichitr V, Hin ATT, Suyono S, Lee YT. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low‐density lipoprotein‐cholesterol ‐ a multinational, multicenter, double‐blind study. Journal of the Formosa Medical Association 2002;101(7):478‐87. [MEDLINE: ] - PubMed
Wu 2005 {published data only}
    1. Wu SC, Shiang JC, Lin SL, Wu TL, Huang WC, Chiou KR, et al. Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins. Heart & Vessels 2005;20(5):217‐23. [MEDLINE: ] - PubMed
Yoshitomi 2005 {published data only}
    1. Yoshitomi Y, Ishii T, Kaneki M, Tsujibayashi T, Sakurai S, Nagakura C, et al. Relationship between insulin resistance and effect of atorvastatin in non‐diabetic subjects. Journal of Atherosclerosis & Thrombosis 2005;12(1):9‐13. [MEDLINE: ] - PubMed
ZAPE 2003 {unpublished data only}
    1. Munoz MT, Alonso M, Oyarzabal M, Mainou C, Fabiani F, Sol JM, et al. Safety and efficacy of atorvastatin vs colestipol in children and adolescents with familial hypercholesterolemia. Circulation 2003;108 Suppl 4:IV‐689. [PREV200400052747]
    1. Pfizer Inc. A 1 Year, Open‐Label, Randomized Parallel Group Multicenter Study for the Comparison of Atorvastatin vs. Colestipol on the Treatment of Children and Adolescents with Familial Hypercholesterolemia (FH) and Hypercholesterolemia. Protocol 981‐336 2003.
Zhu 2000 {published data only}
    1. Zhu Q. Effects of atorvastatin treatment on the oxidatively modified low‐density lipoprotein in hyperlipidemic patients. MAI 38/01 2000:p116. [ProQuest document ID: 732074361] - PubMed
    1. Zhu Q, McMaster J, Mymin D, Dembinski T, Hatch G, Choy PC, et al. Effects of atorvastatin treatment on the oxidatively modified low density lipoprotein in hyperlipidemic patients. Molecular and Cellular Biochemistry 2000;207(1):9‐17. [MEDLINE: ] - PubMed

References to studies excluded from this review

ACTFAST 2 2004 {published data only}
    1. Farsang C. Athyros V. Gaw A. ACTFAST‐2 Investigators and Steering Committee Members. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL‐C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST‐2) study. Current Medical Research & Opinion 2007;23(8):1945‐56. [MEDLINE: ] - PubMed
    1. Pfizer Inc. Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration: a Multicenter, Twelve‐week Treatment, Single‐step Titration, Open‐label Study Assessing the Percentage of Dyslipidemic High‐risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL‐C) Target with Atorvastatin Starting Doses of 10 mg, 20 mg, 40 mg, and 80 mg. Protocol No. A2581095 2004.
ADSL 2003 {unpublished data only}
    1. Pfizer. The atorvastatin efficacy and safety study in diabetic patients to determine starting dose for effectively reducing lipids (the ADSL study). Protocol No. A2581080 2003.
Ahmed 2008 {published data only}
    1. Ahmed S, Ullah E, Ahmed M, Abbas R, Khan MA, Iqbal J. Efficacy of combination of ezetimibe and simvastatin versus atorvastatin in reducing low density lipoprotein‐cholesterol in male patients of hypercholesterolemia, at Bahawalpur. Medical Forum Monthly. Medical Forum (Monthly) (Gujjar Singh, Lahore 5460, Pakistan), 2008; Vol. 19, issue 5:3‐9.
Alrasadi K 2008 {published data only}
    1. Alrasadi K, Awan Z, Alwaili K, Ruel I, Hafiane A, Krimbou L, et al. Comparison of treatment of severe high‐density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended‐release niacin (2 g). American Journal of Cardiology 2008;102(10):1341‐7. [MEDLINE: ] - PubMed
Alvarez 1999 {published data only}
    1. Alvarez ML, Errasti P, Gomez G, Lavilla FJ, Ballester B, Garcia I, et al. Effect of atorvastatin of the treatment of hypercholesterolemia after renal transplantation. Transplantation Proceedings 1999;31(6):2328‐9. [MEDLINE: ] - PubMed
Arad 2005 {published data only}
    1. Arad Y, Newstein D, Roth M, Guerci AD. Rationale and design of the St. Francis Heart Study: a randomized clinical trial of atorvastatin plus antioxidants in asymptomatic persons with elevated coronary calcification. Controlled Clinical Trials 2001;22(5):553‐72. [MEDLINE: ] - PubMed
    1. Arad Y, Spadaro LA, Roth M, Newstein D, Guerci AD. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. Journal of the American College of Cardiology 2005;46(1):166‐72. [MEDLINE: ] - PubMed
Argent 2003 {published data only}
    1. Argent E, Kainer G, Aitken M, Rosenberg AR, Mackie FE. Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients. Pediatric Transplantation 2003;7(1):38‐42. [MEDLINE: ] - PubMed
ASG 2008 {published data only}
    1. Atorvastatin Study Group. Flexible initial dosing of atorvastatin based upon initial low‐density lipoprotein cholesterol levels in type 2 diabetic patients. Korean Journal of Internal Medicine 2008;23(1):22‐9. [MEDLINE: ] - PMC - PubMed
AstraZeneca 3 {unpublished data only}
    1. AstraZeneca. A Multicenter, Randomized, Double‐blind, Parallel‐group, Dose Titration (10 mg and 20 mg) Study to Compare the Efficacy and Safety of Rosuvastatin versus Atorvastatin in Patients with Primary Hypercholesterolemia. Protocol No. 4522SP/0001 2004.
AstraZeneca 4 {unpublished data only}
    1. AstraZeneca. A 6‐week, Randomised, Open‐label, Parallel Group, Multi‐centre Study to Compare the Efficacy of Rosuvastatin 10mg with Atorvastatin 10mg in the Treatment of Non‐diabetic Metabolic Syndrome Subjects with Raised LDL‐C. Protocol No. D3560L00053 2007.
ATGOAL 2005 {published data only}
    1. McKenney JM, Davidson MH, Saponaro J, Thompson PD, Bays HE. Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. Journal of Cardiovascular Pharmacology 2005;46(5):594‐9. [MEDLINE: ] - PubMed
    1. Pfizer Inc. A Multicenter, Eight‐Week Treatment, Single Step Titration, Open‐Label Study Assessing the Percentage of Dyslipidemic Patients Achieving Low Density Lipoprotein Cholesterol (LDL‐C) Target with Atorvastatin Starting Doses of 10 mg, 20 mg, 40 mg, and 80 mg (AT GOAL). Protocol No. A2581068 2002. - PubMed
    1. Pfizer Inc. A Multicenter, Eight‐Week Treatment, Single Step Titration, Open‐Label Study Assessing the Percentage of Dyslipidemic Subjects Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin Starting Doses of 10 mg, 20 mg, 40 mg, and 80 mg (Latin American Atorvastatin ATGOAL Study). Protocol No. A2581104 2005.
Athyros 2008 {published data only}
    1. Athyros VG, Tziomalos K, Kakafika AI, Koumaras H, Karagiannis A, Mikhailidis DP, et al. Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10 mg) for statin intolerant high‐risk patients. American Journal of Cardiology 2008;101(4):483‐5. - PubMed
Atorvastatin 2008 {published data only}
    1. Atorvastatin Study Group. Flexible initial dosing of atorvastatin based upon initial low‐density lipoprotein cholesterol levels in type 2 diabetic patients. Korean Journal of Internal Medicine 2008;23(1):22‐9. - PMC - PubMed
Banyai 2001 {published data only}
    1. Banyai S, Banyai M, Falger J, Jansen M, Alt E, Derfler K, et al. Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long‐term LDL apheresis treatment. Atherosclerosis 2001;159(2):513‐9. [MEDLINE: ] - PubMed
Boh 2011 {published data only}
    1. Boh M, Opolski G, Poredos P, Ceska R, Jezovnik M. Therapeutic equivalence of the generic and the reference atorvastatin in patients with increased coronary risk. International Angiology 2011;30(4):366‐74. [CENTRAL: CN‐00798821] - PubMed
Bolewski 2008 {published data only}
    1. Bolewski A, Lipiecki J, Plewa R, Burchardt P, Siminiak T. The effect of atorvastatin treatment on lipid profile and adhesion molecule levels in hypercholesterolemic patients: relation to low‐density lipoprotein receptor gene polymorphism. Cardiology 2008;111(2):140‐6. [MEDLINE: ] - PubMed
Bonet 2002 {published data only}
    1. Bonet LA, Martinez‐Dolz L, Vives A, Soriano JR, Saez AO, Gisbert FD, et al. Lipid‐lowering effect of atorvastatin in heart transplantation. Transplantation Proceedings 2002;34(1):179‐81. [MEDLINE: ] - PubMed
Brown 2004 {published data only}
    1. Brown SL, Raal FJ, Panz VR, Stevens BA, Veller MG. High‐dose atorvastatin therapy is required for significant improvement of endothelial function in heterozygous familial hypercholesterolaemic patients. Cardiovascular Journal of Southern Africa 2004;15(2):70‐5. [MEDLINE: ] - PubMed
CAPABLE {unpublished data only}
    1. Ferdinand KC, Flack JM, Saunders E, Victor R, Watson K, Kursun A, et al. Amlodipine/atorvastatin single‐pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus. Journal of Clinical Hypertension 2009; Vol. 11, issue 10:585‐93. - PMC - PubMed
    1. Flack JM, Victor R, Watson K, Ferdinand KC, Saunders E, Tarasenko L, et al. Improved attainment of blood pressure and cholesterol goals using single‐pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clinic Proceedings 2008;83(1):35‐45. [MEDLINE: ] - PubMed
    1. Pfizer Inc. Clinical Utility of CADUET in Simultaneously Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population (CAPABLE). Protocol No. A3841025 2005.
Carnevale 2010 {published data only}
    1. Carnevale R, Pignatelli P, Santo S, Bartimoccia S, Sanguigni V, Napoleone L, et al. Atorvastatin inhibits oxidative stress via adiponectin‐mediated NADPH oxidase down‐regulation in hypercholesterolemic patients. Atherosclerosis 2010;213(1):225‐34. - PubMed
COMPELL 2007 {published data only}
    1. McKenney JM, Jones PH, Bays HE, Knopp RH, Kashyap ML, Ruoff GE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended‐release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007;192(2):432‐7. [MEDLINE: ] - PubMed
Conard 2008 {published data only}
    1. Conard SE, Bays HE, Leiter LA, Bird SR, Rubino J, Lowe RS, et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus up‐titration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. The American Journal of Cardiology 2008; Vol. 102, issue 11:1489‐94. - PubMed
Costa 2003 {published data only}
    1. Costa A, Casamitjana R, Casals E, Alvarez L, Morales J, Masramon X, et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C‐reactive protein in subjects with impaired fasting glucose. Diabetic Medicine 2003;20(9):743‐5. [MEDLINE: ] - PubMed
Davis 2000 {published data only}
    1. Davis M, Atwal AS, Nair DR, Jagroop IA, Seifalian AM, Mikhailidis DP, et al. The effect of short‐term lipid lowering with atorvastatin on carotid artery media thickness in patients with peripheral vascular disease: a pilot study. Current Medical Research and Opinion 2000;16(3):198‐204. [MEDLINE: ] - PubMed
Di Renzo 2008 {published data only}
    1. Renzo L, Noce A, Angelis S, Miani N, Daniele N, Tozzo C, et al. Anti‐inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome. Pharmacological Research 2008;57(2):93‐9. [MEDLINE: ] - PubMed
DISCOVERY PENTA 2005 {published data only}
    1. Fonseca FA, Ruiz A, Cardona‐Munoz EG, Silva JM, Fuenmayor N, Marotti M. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL‐C Value ‐ an Evaluation of Rosuvastatin therapY compared with atorvastatin. Current Medical Research & Opinion 2005;21(8):1307‐15. [MEDLINE: ] - PubMed
Dogra 2002 {published data only}
    1. Dogra GK, Watts GF, Herrmann S, Thomas MA, Irish AB. Statin therapy improves brachial artery endothelial function in nephrotic syndrome. Kidney International 2002;62(2):550‐7. [MEDLINE: ] - PubMed
Dujovne 2000 {published data only}
    1. Dujovne CA, Harris WS, Altman R, Overhiser RW, Black DM. Effect of atorvastatin on hemorheologic‐hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. American Journal of Cardiology 2000;85(3):350‐3. [MEDLINE: ] - PubMed
Faludi 2004 {published data only}
    1. Faludi AA, Aldrighi JM, Bertolami MC, Saleh MH, Silva RA, Nakamura Y, et al. Progesterone abolishes estrogen and/or atorvastatin endothelium dependent vasodilatory effects. Atherosclerosis 2004;177(1):89‐96. [MEDLINE: ] - PubMed
Farsang 2007 {published data only}
    1. Farsang C, Athyros V, Gaw A, Investigators and Steering Committee Members. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL‐C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST‐2) study. Current Medical Research & Opinion 2007;23(8):1945‐56. [MEDLINE: ] - PubMed
Ferrer‐Garcia 2008 {published data only}
    1. Ferrer‐Garcia JC, Sanchez‐Ballester E, Albalat‐Galera R, Berzosa‐Sanchez M, Herrera‐Ballester A. Efficacy of atorvastatin for achieving cholesterol targets after LDL‐cholesterol based dose selection in patients with type 2 diabetes. Journal of Cardiovascular Pharmacology & Therapeutics 2008;13(3):183‐8. [MEDLINE: ] - PubMed
Gandelman 2011 {published data only}
    1. Gandelman K, Glue P, Laskey R, Jones J, LaBadie R, Ose L. An eight‐week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia. Pediatric Cardiology 2011;32(4):433‐41. [MEDLINE: ] - PMC - PubMed
Geiss 1999 {published data only}
    1. Geiss HC, Parhofer KG, Schwandt P. Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis. Journal of Internal Medicine 1999;245(1):47‐55. [MEDLINE: ] - PubMed
Goldammer 2002 {published data only}
    1. Goldammer A, Wiltschnig S, Heinz G, Jansen M, Stulnig T, Horl WH, et al. Atovastatin in low‐density lipoprotein apheresis‐treated patients with homozygous and heterozygous familial hypercholesterolemia. Metabolism: Clinical & Experimental 2002;51(8):976‐80. [MEDLINE: ] - PubMed
Gupta 2004 {published data only}
    1. Gupta A, Gupta V, Thapar S, Bhansali A. Lipid‐lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. American Journal of Ophthalmology 2004;137(4):675‐82. [MEDLINE: ] - PubMed
Ishigami 2003 {published data only}
    1. Ishigami M, Yamashita S, Sakai N, Hirano K‐I, Hiraoka H, Nakamura T, et al. Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B‐containing lipoproteins. Atherosclerosis 2003;168(2):359‐66. [MEDLINE: ] - PubMed
Jafari 2003 {published data only}
    1. Jafari M, Ebrahimi R, Ahmadi‐Kashani BS, Balian H, Bashir M. Efficacy of alternate‐day dosing versus daily dosing of atorvastatin. Journal of Cardiovascular Pharmacology & Therapeutics 2003;8(2):123‐6. [MEDLINE: ] - PubMed
Jose 2012 {published data only}
    1. Jose MA, Anandkumar S, Narmadha MP, Sandeep M. A comparative effect of atorvastatin with other statins in patients of hyperlipidemia. Indian Journal of Pharmacology 2012;44(2):261‐3. [MEDLINE: ] - PMC - PubMed
Jyoti 2008 {published data only}
    1. Jyoti N, Rai J, Singh S. Comparative evaluation of atorvastatin and rosuvastatin in patients of dyslipidemia. JK Practitioner. India: JK Practitioner (P.O. Box 884, Srinagar, Kashmir 190001, India), 2008; Vol. 15, issue 1‐4:27‐35.
Kaya 2009 {published data only}
    1. Kaya C, Cengiz SD, Berker B, Demirtas S, Cesur M, Erdogan G, et al. Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study. Fertility & Sterility 2009;92(2):635‐42. [MEDLINE: ] - PubMed
Kearns 2008 {published data only}
    1. Kearns AK, Bilbie CL, Clarkson PM, White CM, Sewright KA, O'Fallon KS, et al. The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg. Atherosclerosis 2008;200(1):121‐5. [MEDLINE: ] - PubMed
Krysiak 2010 {published data only}
    1. Krysiak R, Gdula‐Dymek A, Bachowski R, Okopien B, Krysiak R, Gdula‐Dymek A, et al. Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre‐diabetes. Diabetes Care 2010;33(10):2266‐70. [MEDLINE: ] - PMC - PubMed
Lamon‐Fava 2007 {published data only}
    1. Lamon‐Fava S, Diffenderfer MR, Barrett PH, Buchsbaum A, Matthan NR, Lichtenstein AH, et al. Effects of different doses of atorvastatin on human apolipoprotein B‐100, B‐48, and A‐I metabolism. Journal of Lipid Research 2007;48(8):1746‐53. [MEDLINE: ] - PubMed
Lee 2010 {published data only}
    1. Lee CW, Baek SH, Hong TJ, Choi YJ, Kim YJ, Ahn TH, et al. A multicenter, eight‐week treatment, single‐step titration, open‐label study assessing the percentage of Korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mg. Cardiovascular Drugs & Therapy 2010;24(2):181‐8. [MEDLINE: ] - PubMed
Lundberg 2010 {published data only}
    1. Lundberg S, Lundahl J, Gunnarsson I, Jacobson SH. Atorvastatin‐induced modulation of monocyte respiratory burst in vivo in patients with IgA nephropathy: a chronic inflammatory kidney disease. Clinical Nephrology. Germany: Nephrology Unit, Division of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden. sigrid.lundberg@karolinska.se, 2010; Vol. 73, issue 3:221‐8. - PubMed
McVey 1999 {published data only}
    1. McVey D, Patel H, Eminton Z, Maton S. An assessment of the efficacy of atorvastatin in treating patients with dyslipidaemia to target LDL‐cholesterol goals: the atorvastatin matrix study. International Journal of Clinical Practice 1999;53(7):509‐13. [MEDLINE: ] - PubMed
Meas 2009 {published data only}
    1. Meas T, Laloi‐Michelin M, Virally M, Peynet J, Giraudeaux V, Kevorkian JP, et al. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile. European Journal of Internal Medicine 2009;20(2):197‐200. [MEDLINE: ] - PubMed
Nawawi 2003 {published data only}
    1. Nawawi H, Osman NS, Yusoff K, Khalid BA. Reduction in serum levels of adhesion molecules, interleukin‐6 and C‐reactive protein following short‐term low‐dose atorvastatin treatment in patients with non‐familial hypercholesterolemia. Hormone & Metabolic Research 2003;35(8):479‐85. [MEDLINE: ] - PubMed
Nicholls 2011 {published data only}
    1. Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011;306(19):2099‐109. [MEDLINE: ] - PubMed
Paolisso 2000 {published data only}
    1. Paolisso G, Barbagallo M, Petrella G, Ragno E, Barbieri M, Giordano M, et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non‐insulin dependent diabetic patients. Atherosclerosis 2000;150(1):121‐7. [MEDLINE: ] - PubMed
Perez‐Castrillon 2007 {published data only}
    1. Perez‐Castrillon JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G, et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. American Journal of Cardiology 2007;99(7):903‐5. [MEDLINE: ] - PubMed
Pfizer Inc 10 {unpublished data only}
    1. Pfizer Inc. A Multicenter, Eight‐week Treatment, Single‐step Titration, Open‐label Study Assessing the Percentage of Dyslipidemic Patients Achieving LDL Cholesterol Target with Atorvastatin Starting Doses of 10 mg, 20 mg and 40 mg. Protocol No. A2581111 2004. - PubMed
Pfizer Inc 11 {unpublished data only}
    1. Pfizer Inc. A Phase 3, Double‐Blind, Randomized, Multisite Trial of the Efficacy, Safety, and Tolerability of the Fixed Combination Torcetrapib/atorvastatin Administered Orally, Once Daily for 12 Months, Compared to Atorvastatin Alone, Titrated Based on NCEP ATP‐III LDL‐C Goals in Subjects with Fredrickson Types IIa and IIb Dyslipidemia. Protocol No. A5091019 2006.
Pfizer Inc 13 {unpublished data only}
    1. Pfizer Inc. Phase 3, Multi‐site, Double‐blind, Randomized, Forced Titration, Parallel Group Evaluation of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib(CP‐529‐414)/atorvastatin Administered Orally, Once Daily (QD) for Eighteen Weeks, Compared with Atorvastatin Alone, in Subjects with Fredrickson Type IV Hypertriglyceridemia. Protocol No. A5091025 2006.
Pfizer Inc 14 {unpublished data only}
    1. Pfizer Inc. Phase 3, Multi‐center, Double‐blind, Randomized, Crossover Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP‐529,414)/atorvastatin, Compared with Atorvastatin Therapy Alone, and Fenofibrate Alone, in Subjects with Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia). Protocol No. A5091024 2006.
Pfizer Inc 5 {unpublished data only}
    1. Pfizer Inc. A Multicenter, Twelve‐week Treatment, Single‐step Titration Open‐label Study Assessing the Percentage of Dyslipidemic High‐risk Patients Achieving LDL Cholesterol Targets with Atorvastatin Starting Doses of 10 mg, 20 mg, and 40 mg. Protocol No. A2581099 2004. - PubMed
Puccetti 2001 {published data only}
    1. Puccetti L, Bruni F, Bova G, Cercignani M, Palazzuoli A, Console E, et al. Effect of diet and treatment with statins on platelet‐dependent thrombin generation in hypercholesterolemic subjects. Nutrition Metabolism & Cardiovascular Diseases 2001;11(6):378‐87. [MEDLINE: ] - PubMed
Puccetti 2011 {published data only}
    1. Puccetti L, Santilli F, Pasqui AL, Lattanzio S, Liani R, Ciani F, et al. Effects of atorvastatin and rosuvastatin on thromboxane‐dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis. Ireland: Center for Atherosclerosis Research, University of Siena, v.le Bracci, 53100 Siena, Italy. puccetti@unisi.it, 2011; Vol. 214, issue 1:122‐8. - PubMed
Riahi 2006 {published data only}
    1. Riahi S, Schmidt EB, Amanavicius N, Karmisholt J, Jensen HS, Christoffersen RP, et al. The effect of atorvastatin on heart rate variability and lipoproteins in patients treated with coronary bypass surgery. International Journal of Cardiology 2006;111(3):436‐41. [MEDLINE: ] - PubMed
Riesen 2002 {published data only}
    1. Riesen WF, Engler H, Risch M, Korte W, Noseda G. Short‐term effects of atorvastatin on C‐reactive protein. European Heart Journal 2002;23(10):794‐9. [MEDLINE: ] - PubMed
Roberto 2010 {published data only}
    1. Roberto C, Pasquale P, Serena DS, Simona B, Valerio S, Laura N, et al. Atorvastatin inhibits oxidative stress via adiponectin‐mediated NADPH oxidase down‐regulation in hypercholesterolemic patients. Atherosclerosis. Ireland: Elsevier Ireland Ltd (P.O. Box 85, Limerick, Ireland), 2010; Vol. 213, issue 1:225‐34. - PubMed
Schaefer 2002 {published data only}
    1. Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JA, Seman LJ, et al. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. American Journal of Cardiology 2002;90(7):689‐96. [MEDLINE: ] - PubMed
Schaefer 2004 {published data only}
    1. Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JL, Seman LJ, et al. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. American Journal of Cardiology 2004;93(1):31‐9. [MEDLINE: ] - PubMed
Schuster 1998 {published data only}
    1. Schuster H, Berger J, Luft FC. Randomized, double‐blind, parallel‐group trial of atorvastatin and fluvastatin on plasma lipid levels in patients with untreated hyperlipidaemia. British Journal of Cardiology 1998;5(11):597‐602. [EMBASE: 1998398852]
Soedamah‐Muthu 2003 {published data only}
    1. Soedamah‐Mathu SS, Colhoun HM, Thomason MJ, Betteridge DJ, Durrington PN, Hitman GA, et al. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis 2003;167(2):243‐55. [MEDLINE: ] - PubMed
Son 2013 {published data only}
    1. Son JW, Kim DJ, Lee CB, Oh S, Song KH, Jung CH, et al. Effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes. Journal of Diabetes Investigation 2013;4(5):466‐74. [Biosis PREV201300771684] - PMC - PubMed
Sparks 2005 {published data only}
    1. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Petanceska S, et al. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild‐to‐moderate AD. Current Alzheimer Research 2005;2(3):343‐53. [MEDLINE: ] - PubMed
Tutunov 2008 {published data only}
    1. Tutunov VS, Popkova TV, Novikova DS, Nasonov EL, Kukhrchuk VV, Tutunov VS, et al. Comparative assessment of antiinflammatory action of atorvastatin in ischemic heart disease and rheumatoid arthritis. Kardiologiia 2008;48(9):4‐8. [MEDLINE: ] - PubMed
Undas 2006b {published data only}
    1. Undas A, Celinska‐Lowenhoff M, Lowenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. Journal of Thrombosis & Haemostasis 2006;4(5):1029‐36. [MEDLINE: ] - PubMed
VYMET 2009 {published data only}
    1. Robinson JG, Ballantyne CM, Grundy SM, Hsueh WA, Parving HH, Rosen JB, et al. Lipid‐altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). American Journal of Cardiology 2009;103(12):1694‐703. [MEDLINE: ] - PubMed
    1. Robinson JG, Ballantyne CM, Hsueh W, Rosen J, Lin J, Shah A, et al. Achievement of specified low‐density lipoprotein cholesterol, non‐high‐density lipoprotein cholesterol apolipoprotein B, and high‐sensitivity C‐reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). Journal of Clinical Lipidology 2011;5(6):474‐82. [MEDLINE: ] - PubMed
    1. Robinson JG, Ballantyne CM, Hsueh WA, Rosen JB, Lin J, Shah AK, et al. Age, abdominal obesity, and baseline high‐sensitivity C‐reactive protein are associated with low‐density lipoprotein cholesterol, non‐high‐density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. Journal of Clinical Lipidology 2013;7(4):292‐303. [MEDLINE: ] - PubMed
    1. Villa J, Pratley RE. Ezetimibe/simvastatin or atorvastatin for the treatment of hypercholesterolemia in patients with the metabolic syndrome: the VYMET study. Current Diabetes Reports. Current Medicine Group LLC (5 Marine View Plaza, Suite 218, Hoboken NJ 07030, United States), 2010; Vol. 10, issue 3:173‐5. - PubMed
Wanner 2005 {published data only}
    1. Marz W, Genser B, Drechsler C, Krane V, Grammer TB, Ritz E, et al. Atorvastatin and low‐density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis: associated excluded citation for the Wanner 2005 trial. Clinical Journal of the American Society of Nephrology (CJASN) 2011;6(6):1316‐25. [MEDLINE: ] - PMC - PubMed
    1. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine 2005;353(3):238‐48. [MEDLINE: ] - PubMed
Wierzbicki 1999 {published data only}
    1. Wierzbicki AS, Christ ER, Chik G, Lumb PJ, Semra YK, Crook MA. A comparison of atorvastatin with previous therapy in treatment of patients with severe hyperlipidaemias. Atherosclerosis 1999;144 Suppl 1:34. [IDS Number: 203BM]
    1. Wierzbicki AS, Lumb PJ, Cheung J, Crook MA. Fenofibrate‐simvastatin therapy compared to simvastatin‐resin therapy and atorvastatin for familial hypercholesterolaemia. Atherosclerosis 1997;134(1‐2):63. [CENTRAL: CN‐00448364]
    1. Wierzbicki AS, Lumb PJ, Semra Y, Chik G, Christ ER, Crook MA. Atorvastatin compared with simvastatin‐based therapies in the management of severe familial hyperlipidaemias. Quarterly Journal of Medicine 1999;92(7):387‐94. [MEDLINE: ] - PubMed
Winkler 2004 {published data only}
    1. Weltzien P, Winkler K, Friedrich I, Schmitz H, Hauck P, Hoffmann M, et al. Fenofibrate and atorvastatin in patients with combined hyperlipidemia and dense low density lipoproteins. Diabetologia 2002;45 Suppl 2:A389. [IDS Number: 590HM]
    1. Winkler K, Weltzien P, Friedrich I, Schmitz H, Nickell HH, Hauck P, et al. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL. Experimental & Clinical Endocrinology & Diabetes 2004;112(5):241‐7. [MEDLINE: ] - PubMed
Yamamoto 2000 {published data only}
    1. Yamamoto A, Harada‐Shiba M, Kawaguchi A, Oi K, Kubo H, Sakai S, et al. The effect of atorvastatin on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL‐apheresis therapy. Atherosclerosis 2000;153(1):89‐98. [MEDLINE: ] - PubMed
Yang 2007 {published data only}
    1. Yang B, Shi X‐M, Ma C‐Y, Feng X‐Y, Liu K, Chen D, et al. Relationship between serum uric acid and carotid intima‐media thickness in Tibetan: effect of atorvastatin therapy on hyperuricemia. Journal of Clinical Rehabilitative Tissue Engineering Research 2007;11(21):4248‐50. [EMBASE: 2007338185]
Yildiz 2007 {published data only}
    1. Yildiz A, Cakar MA, Baskurt M, Okcun B, Guzelsoy D, Coskun U. The effects of atorvastatin therapy on endothelial function in patients with coronary artery disease. Cardiovascular Ultrasound 2007;5:51. [MEDLINE: ] - PMC - PubMed
Yilmaz 2005 {published data only}
    1. Yilmaz AK, Kayardi M, Toktamis A, Tomul ZD, Nur N. The effects of clarithromycin added to atorvastatin treatment on serum lipid profiles: a randomised clinical trial. Pakistan Journal of Medical Sciences 2005;21(2):174‐7. [EMBASE: 2005315853]

Additional references

Abramson 2013
    1. Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin?. BMJ 2013;347:f6123. [MEDLINE: ] - PubMed
Adams 2014
    1. Adams SP, Sekhon SS, Wright JM. Rosuvastatin for lowering lipids. Cochrane Database of Systematic Reviews 2014, Issue 11. [DOI: 10.1002/14651858.CD010254] - DOI - PMC - PubMed
Bandolier 2004
    1. Bandolier. Cholesterol lowering with statins. Bandolier 2004:121‐2.
CDC 2011
    1. Centers for Disease Control and Prevention (CDC). Million hearts: strategies to reduce the prevalence of leading cardiovascular disease risk factors ‐‐ United States, 2011. MMWR ‐ Morbidity & Mortality Weekly Report 2011;60(36):1248‐51. [MEDLINE: ] - PubMed
CTT 2005
    1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol‐lowering treatment: prospective meta‐analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267‐78. [MEDLINE: ] - PubMed
Edwards 2003
    1. Edwards JE, Moore RA. Statins in hypercholesterolaemia: a dose‐specific meta‐analysis of lipid changes in randomised, double blind trials. BMC Family Practice 2003;4:18. [MEDLINE: ] - PMC - PubMed
Elmberger 1991
    1. Elmberger PG, Kalen A, Lund E, Reihner E, Eriksson M, Berglund L, Angelin B, Dallner G. Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia. Journal of Lipid Research 1991;32(6):935‐40. [MEDLINE: ] - PubMed
Furukawa 2006
    1. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7‐10. [MEDLINE: ] - PubMed
Gaw 2000
    1. Gaw A, Packard CJ, Shepherd J. Statins: The HMG CoA Reductase Inhibitors in Perspective. London, England: Martin Dunitz Ltd, 2000. [ISBN 1853174688]
Goodman 2011
    1. Goodman LS, Brunton LL, Chabner B, Knollmann BC. Goodman & Gilman's Pharmacological Basis of Therapeutics. 12th Edition. New York: McGraw‐Hill, 2011. [ISBN: 9780071624428]
Grundy 2004
    1. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology 2004;44(3):720‐32. [MEDLINE: ] - PubMed
Heran 2008
    1. Heran BS, Wong MMY, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003823.pub2] - DOI - PMC - PubMed
Higgins 2002
    1. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58. [MEDLINE: ] - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org, 2011.
Holmqvist 2008
    1. Schmidt A. Non‐lipid lowering effects of statins. In: Gunnar N Holmqvist editor(s). Statins: Indications and Uses, Safety and Modes of Action. 1. New York: Nova Science, Inc, Dec 2008:73‐90. [ISBN‐10: 1606921037 ISBN‐13: 978‐1606921036]
IMS 2012
    1. Institute for Health Informatics. The use of medicines in the United States: review of 2011. Medicines in US Report 2012:32.
Kreatsoulas 2010
    1. Kreatsoulas C, Anand SS. The impact of social determinants on cardiovascular disease. Canadian Journal of Cardiology 2010;26(Suppl C):8C‐13C. [MEDLINE: ] - PMC - PubMed
Law 2003
    1. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta‐analysis. BMJ 2003;326(7404):1423. [MEDLINE: ] - PMC - PubMed
Liao 2005
    1. Liao JK, Laufs U. Pleiotropic effects of statins. Annual Review of Pharmacology and Toxicology 2005;45:89‐118. [MEDLINE: ] - PMC - PubMed
Lins 2003
    1. Lins RL, Matthys KE, Verpooten GA, Peeters PC, Dratwa M, Stolear JC, Lameire NH. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrology Dialysis Transplantation 2003;18(5):967‐76. [MEDLINE: ] - PubMed
Lipitor Prescribing Information 2012
    1. Highlights of Prescribing Information, 2012. labeling.pfizer.com/ShowLabeling.aspx?id=587 (accessed 8 November 2012).
Marcoff 2007
    1. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin‐associated myopathy: a systematic review. Journal of the American College of Cardiology 2007;49(23):2231‐7. [MEDLINE: ] - PubMed
Mills 2008
    1. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta‐analysis involving more than 65,000 patients. Journal of the American College of Cardiology 2008;52(22):1769‐81. [MEDLINE: ] - PubMed
Moghadasian 1999
    1. Moghadasian MH. Clinical pharmacology of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors. Life Sciences 1999;65(13):1329‐37. [MEDLINE: ] - PubMed
Naci 2013
    1. Naci H, Brugts JJ, Fleurence R, Ades AE. Dose‐comparative effects of different statins on serum lipid levels: a network meta‐analysis of 256,827 individuals in 181 randomized controlled trials. European Journal of Preventive Cardiology 2013;20(4):658‐70. [MEDLINE: ] - PubMed
NCEP 2002
    1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143‐421. [MEDLINE: ] - PubMed
RevMan 2011 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Roger 2011
    1. Roger VL, Go AS, Lloyd‐Jones DM, Adams RJ, Berry JD, Brown TM, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics ‐‐ 2011 update: a report from the American Heart Association. Circulation 2011;123(4):e18‐e209. [MEDLINE: ] - PMC - PubMed
Schachter 2004
    1. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundamental & Clinical Pharmacology 2004;19(1):117‐25. [MEDLINE: ] - PubMed
Smith 2009
    1. Smith MEB, Lee NJ, Haney E, Carson S. Drug Class Review. HMG‐CoA Reductase Inhibitors (Statins) and Fixed‐dose Combination Products Containing a Statin. Final Report Update 5, 2009. www.ncbi.nlm.nih.gov/books/NBK47273/pdf/TOC.pdf (last accessed 8 November 2012). - PubMed
Taylor 2013
    1. Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD004816.pub5] - DOI - PMC - PubMed
Therapeutics Initiative 2010
    1. Therapeutics Initiative. Do statins have a role in primary prevention? An update. Therapeutics Letter 2010;77(Mar‐Apr):1‐2.
Thompson 2005
    1. Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, Banerjee P, Milos PM, Myrand SP, Paulauskis J, Milad MA, Sasiela WJ. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics Journal 2005;5(6):352‐8. [MEDLINE: ] - PubMed
Tsang 2002
    1. Tsang MB, Adams SP, Jauca C, Wright JM. In Some Systematic Reviews Placebos May Not Be Necessary: An Example From a Statin Dose‐Response Study. 10th Cochrane Colloquium Abstracts; 2002 31 Jul‐3 Aug; Stavanger, Norway. 2002:Poster 29.
Uusitupa 1992
    1. Uusitupa MIJ, Miettinen TA, Happonen P, Ebeling T, Turtola H, Voutilainen E, Pyorala K. Lathosterol and other noncholesterol sterols during treatment of hypercholesterolemia with lovastatin alone and with cholestyramine or guar gum. Arteriosclerosis & Thrombosis 1992;12(7):807‐13. [MEDLINE: ] - PubMed

References to other published versions of this review

Adams 2010
    1. Wright JM, Adams SP, Tsang M. Lipid lowering efficacy of atorvastatin. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD008226] - DOI
Adams 2012
    1. Adams SP, Tsang M, Wright JM. Lipid lowering efficacy of atorvastatin. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008226.pub2] - DOI - PubMed

Publication types